[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5792
1. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR: The BCL-2 family reunion. Mol Cell; 2010 Feb 12;37(3):299-310
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • B cell CLL/lymphoma-2 (BCL-2) and its relatives comprise the BCL-2 family of proteins, which were originally characterized with respect to their roles in controlling outer mitochondrial membrane integrity and apoptosis.
  • Here we will discuss the mechanisms and functions of the BCL-2 family in the context of these pathways, highlighting the complex integration and regulation of the BCL-2 family in cell fate decisions.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2009 Nov 13;36(3):355-63 [19917245.001]
  • [Cites] Mol Cell. 2009 Nov 13;36(3):487-99 [19917256.001]
  • [Cites] Mol Cell. 2009 Nov 25;36(4):696-703 [19941828.001]
  • [Cites] Nature. 2010 Jan 7;463(7277):103-7 [20023629.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10892-903 [18281291.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):13123-32 [17337444.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):405-13 [17377525.001]
  • [Cites] Apoptosis. 2007 May;12(5):897-911 [17453159.001]
  • [Cites] J Cell Biol. 2007 Apr 23;177(2):277-87 [17452531.001]
  • [Cites] EMBO J. 2007 May 16;26(10):2527-39 [17446862.001]
  • [Cites] Cell Death Differ. 2007 Jun;14(6):1086-94 [17332775.001]
  • [Cites] Autophagy. 2007 Jul-Aug;3(4):374-6 [17438366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11649-54 [17606912.001]
  • [Cites] Genes Dev. 2007 Aug 1;21(15):1937-48 [17671092.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1057-65 [17721514.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):561-8 [17643073.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19500-5 [18048346.001]
  • [Cites] Cell. 2008 Jan 11;132(1):27-42 [18191218.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16202-12 [10821866.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):2060-71 [10950869.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6453-62 [11102440.001]
  • [Cites] Dev Cell. 2001 Oct;1(4):515-25 [11703942.001]
  • [Cites] Dev Cell. 2002 Jan;2(1):55-67 [11782314.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):19-30 [12086884.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):183-92 [12242151.001]
  • [Cites] Cell. 2002 Nov 1;111(3):331-42 [12419244.001]
  • [Cites] J Cell Biol. 2002 Dec 23;159(6):931-8 [12499352.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):577-90 [12667443.001]
  • [Cites] Science. 2003 Apr 4;300(5616):135-9 [12624178.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36373-9 [12783892.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 [14996493.001]
  • [Cites] Nat Cell Biol. 2004 May;6(5):443-50 [15077116.001]
  • [Cites] Mol Biol Cell. 2004 Nov;15(11):5001-11 [15356267.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] Cell. 1989 Apr 7;57(1):79-88 [2649247.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):331-3 [2250704.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13829-34 [9153240.001]
  • [Cites] J Virol. 1998 Nov;72(11):8586-96 [9765397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):105-10 [15613488.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):393-403 [15694340.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1101-4 [15718471.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):525-35 [15721256.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Science. 2005 Sep 9;309(5741):1732-5 [16151013.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35742-50 [16115883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17975-80 [16330765.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):97-108 [16493416.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):761-73 [16543146.001]
  • [Cites] Science. 2006 Apr 28;312(5773):572-6 [16645094.001]
  • [Cites] Cancer Cell. 2006 May;9(5):351-65 [16697956.001]
  • [Cites] Cell. 2006 Jul 14;126(1):163-75 [16839884.001]
  • [Cites] Cell. 2006 Jul 14;126(1):177-89 [16839885.001]
  • [Cites] J Cell Biol. 2006 Sep 25;174(7):915-21 [16982799.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(20):7397-408 [17015472.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4738-45 [16966688.001]
  • [Cites] Nature. 2006 Oct 12;443(7112):658-62 [17035996.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1348-58 [17115033.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):112-21 [17200714.001]
  • [Cites] Science. 2007 Feb 9;315(5813):856-9 [17289999.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):121-32 [18202696.001]
  • [Cites] Dev Cell. 2008 Feb;14(2):193-204 [18267088.001]
  • [Cites] Nat Immunol. 2008 Apr;9(4):405-14 [18327259.001]
  • [Cites] Trends Cell Biol. 2008 Apr;18(4):157-64 [18314333.001]
  • [Cites] Mol Cell. 2008 May 9;30(3):369-80 [18471982.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1029-36 [18443228.001]
  • [Cites] Mol Biol Cell. 2008 Jun;19(6):2402-12 [18353969.001]
  • [Cites] Mol Cell. 2008 Jun 20;30(6):678-88 [18570871.001]
  • [Cites] Nature. 2008 Jul 10;454(7201):232-5 [18454133.001]
  • [Cites] J Biol Chem. 2008 Jul 25;283(30):21294-304 [18524770.001]
  • [Cites] Mol Cell. 2008 Aug 22;31(4):557-69 [18691924.001]
  • [Cites] Mol Cell. 2008 Aug 22;31(4):570-85 [18722181.001]
  • [Cites] Cell Death Differ. 2008 Oct;15(10):1564-71 [18551131.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1076-81 [18948948.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):605-10 [19052620.001]
  • [Cites] Cell. 2008 Dec 12;135(6):1074-84 [19062087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20327-32 [19074266.001]
  • [Cites] Mol Cell. 2009 Jan 16;33(1):15-29 [19150424.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):2719-28 [19029119.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1126-32 [19228717.001]
  • [Cites] Nature. 2009 May 21;459(7245):428-32 [19363473.001]
  • [Cites] Autophagy. 2009 Jul;5(5):720-2 [19395874.001]
  • [Cites] Cell Death Differ. 2009 Aug;16(8):1135-45 [19300452.001]
  • [Cites] Science. 2009 Jul 24;325(5939):477-81 [19556461.001]
  • [Cites] Apoptosis. 2009 Aug;14(8):929-34 [19629695.001]
  • [Cites] Nat Cell Biol. 2009 Aug;11(8):958-66 [19578372.001]
  • [Cites] J Cell Biol. 2009 Aug 10;186(3):355-62 [19651893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14397-402 [19706527.001]
  • (PMID = 20159550.001).
  • [ISSN] 1097-4164
  • [Journal-full-title] Molecular cell
  • [ISO-abbreviation] Mol. Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / F32 CA101444; United States / NIAID NIH HHS / AI / R01 AI040646; United States / NIAID NIH HHS / AI / R01 AI040646-16
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Number-of-references] 89
  • [Other-IDs] NLM/ NIHMS337530; NLM/ PMC3222298
  •  go-up   go-down


2. Hogan M, Claffey J, Pampillón C, Tacke M: Synthesis and cytotoxicity studies of new morpholino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs. Med Chem; 2008 Mar;4(2):91-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When these titanocenes were tested against LLC-PK cells, the IC(50) values obtained were of 24, 36, and 41 microM respectively.
  • The most cytotoxic titanocene in this paper (5a) with an IC(50) value of 24 microM is found to be almost ten times less cytotoxic than cis-platin, which showed an IC(50) value of 3.3 microM when tested on the epithelial pig kidney LLC-PK cell line, and approximately 2 times less cytotoxic than its dimethylamino-functionalised analogue.
  • [MeSH-minor] Animals. Cyclopentanes. Inhibitory Concentration 50. LLC-PK1 Cells. Structure-Activity Relationship. Swine

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336326.001).
  • [ISSN] 1573-4064
  • [Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))
  • [ISO-abbreviation] Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclopentanes; 0 / Morpholines; 0 / Organometallic Compounds; 1271-29-0 / titanocene; 19W699IKIE / fulvene
  •  go-up   go-down


3. da Silva R, Saraiva J, de Albuquerque S, Curti C, Donate PM, Bianco TN, Bastos JK, Silva ML: Trypanocidal structure-activity relationship for cis- and trans-methylpluviatolide. Phytochemistry; 2008 Jun;69(9):1890-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of the compounds was assessed by the MTT method using LLC-MK2 cells.
  • Trans-methylpluviatolide displayed low toxicity for LLC-MK2 cells, with an IC50 of 6.53 mM.
  • [MeSH-minor] Animals. Cell Line. Macrophages / drug effects. Macrophages / metabolism. Mice. Molecular Structure. Nitric Oxide / biosynthesis. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479721.001).
  • [ISSN] 0031-9422
  • [Journal-full-title] Phytochemistry
  • [ISO-abbreviation] Phytochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lactones; 0 / Lignans; 0 / Trypanocidal Agents; 0 / methylpluviatolide; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


Advertisement
4. Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR: Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol; 2010 Nov;151(4):336-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization.
  • Approximately 10% of patients with chronic lymphocytic leukaemia (CLL) have a family history of the disease or a related lymphoproliferative disorder, yet the relationship of familial CLL to genomic abnormalities has not been characterized in detail.
  • We therefore studied 75 CLL patients, half familial and half sporadic, using high-resolution array comparative genomic hybridization (CGH), in order to better define the relationship of genomic abnormalities to familial disease and other biological prognostic factors.
  • Our results showed that the most common high-risk deletion in CLL, deletion 11q, was significantly associated with sporadic disease.
  • Comparison of familial to sporadic disease additionally identified a copy number variant region near the centromere on 14q, proximal to IGH@, in which gains were associated both with familial CLL, and with mutated IGHV and homozygous deletion of 13q.
  • Homozygous deletion of 13q was also found to be associated with mutated IGHV and low expression of ZAP-70, and a significantly longer time to first treatment compared to heterozygous deletion or lack of alteration.
  • This study is the first high resolution effort to investigate and report somatic genetic differences between familial and sporadic CLL.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • [Cites] Br J Haematol. 2000 Jun;109(4):794-9 [10929032.001]
  • [Cites] Leuk Res. 2010 Jan;34(1):63-8 [19406473.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):99-108 [11699227.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1229-32 [12094247.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] N Engl J Med. 1990 Sep 13;323(11):720-4 [2201915.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7 [2052620.001]
  • [Cites] Cancer Invest. 1992;10(2):103-9 [1551021.001]
  • [Cites] Leukemia. 1992 Apr;6(4):246-50 [1588788.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2003-8 [8609709.001]
  • [Cites] Br J Haematol. 1996 Feb;92(2):382-8 [8603004.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1929-32 [9369428.001]
  • [Cites] Leuk Res. 1997 Nov-Dec;21(11-12):1011-23 [9444933.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1382-90 [9454769.001]
  • [Cites] Lancet. 1999 Jan 2;353(9146):26-9 [10023947.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1117-20 [16885053.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1149-58 [16899652.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1202-10 [17053054.001]
  • [Cites] Cytogenet Genome Res. 2007;118(1):8-12 [17901694.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Aug;47(8):697-711 [18484635.001]
  • [Cites] Am J Hematol. 2008 Jul;83(7):540-6 [18161787.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1993-2003 [18436738.001]
  • [Cites] J Mol Diagn. 2008 Sep;10(5):442-51 [18687794.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):1879-86 [18949611.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):361-8 [18729853.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):532-6 [18752589.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1294-303 [18922857.001]
  • [Cites] Leukemia. 2010 Jan;24(1):211-5 [19741724.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 20812997.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA092625; United States / NCI NIH HHS / CA / R21 CA103244; United States / NCI NIH HHS / CA / K23 CA115682; United States / NCI NIH HHS / CA / R01 CA111560; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01-CA081534; United States / NCI NIH HHS / CA / CA-103244; United States / NCI NIH HHS / CA / 2P01CA092625; United States / NCI NIH HHS / CA / CA111560
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS442972; NLM/ PMC3584328
  •  go-up   go-down


5. Akyurek N, Ren Y, Rassidakis GZ, Schlette EJ, Medeiros LJ: Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer; 2006 Oct 15;107(8):1844-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
  • Eight IAPs have been identified in humans, of which cIAP1, cIAP2, and XIAP are well known.
  • METHODS: cIAP1, cIAP2, and XIAP were assessed in lymphoma cell lines, 240 B-cell non-Hodgkin lymphoma (NHL) tumors, and 40 Hodgkin lymphoma (HL) tumors.
  • RESULTS: All IAPs were expressed in most NHL and all HL cell lines.
  • cIAP1 was positive in all precursor B-cell lymphoblastic lymphoma/leukemia (LBL) and nodal marginal zone B-cell lymphoma (MZL), over 90% of follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), and approximately 50% to 60% of myeloma, Burkitt lymphoma (BL), lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM), small lymphocytic lymphoma/ chronic lymphocytic leukemia (SLL/CLL), extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT-lymphoma), splenic MZL, and mantle cell lymphoma. cIAP2 was positive in all MALT-lymphoma, over 90% of precursor B-cell LBL (94%), most BL (75%), LPL/WM (71%), and SLL/CLL (67%), and approximately 40% to 60% of follicular lymphoma, myeloma, and DLBCL.
  • XIAP was positive most cases of precursor B-cell LBL (57%) and approximately 30% to 40% of nodal MZL, BL, and DLBCL.
  • In HL tumors, cIAP1 was positive in 30 (75%), cIAP2 in 27 (68%), and XIAP in 23 (58%), and did not correlate with histologic type.
  • CONCLUSIONS: Differential expression of IAPs in B-cell lymphomas suggests differences in pathogenesis that may have implications for novel treatment strategies targeting IAPs.
  • [MeSH-major] Hodgkin Disease / metabolism. Inhibitor of Apoptosis Proteins / metabolism. Lymphoma, B-Cell / metabolism
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Humans. Immunohistochemistry. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16983704.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


6. Muirhead CR: Chronic lymphocytic leukaemia: an overview of aetiology--comment. Br J Haematol; 2008 Oct;143(2):295-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia: an overview of aetiology--comment.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Radiation, Ionizing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Haematol. 2007 Dec;139(5):672-86 [18021081.001]
  • (PMID = 18710382.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


7. Sayala HA, Rawstron AC, Hillmen P: Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol; 2007 Sep;20(3):499-512
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease assessment in chronic lymphocytic leukaemia.
  • The concept of minimal residual disease (MRD) eradication in chronic lymphocytic leukaemia (CLL) is a relatively new one, as conventional therapy with alkylating agents is relatively ineffective and responding patients almost always have a significant tumour burden remaining at the end of treatment.
  • This progress in therapy has been paralleled by an improvement in laboratory assays, allowing detection of CLL cells to levels as low as ten CLL cells in a million leukocytes.
  • In this chapter we briefly review the existing methods for MRD assessment, the clinical relevance of MRD eradication in CLL, and the therapies available to attain this endpoint.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Alleles. Antibodies, Monoclonal / therapeutic use. Antigens, CD19 / analysis. Antigens, CD5 / analysis. Combined Modality Therapy. Flow Cytometry. Humans. Polymerase Chain Reaction. Sensitivity and Specificity. Stem Cell Transplantation. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707836.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Antigens, CD5; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Number-of-references] 56
  •  go-up   go-down


8. Méhes L, Balázs M, Rejtö L, Telek B, Kiss A, Udvardy M: Chromosomal aberrations and CD38 expression in two siblings with B-cell chronic lymphocytic leukemia: a report of two siblings. Leuk Lymphoma; 2005 Mar;46(3):421-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations and CD38 expression in two siblings with B-cell chronic lymphocytic leukemia: a report of two siblings.
  • In this study our purpose was to define chromosomal aberrations and CD38 expression in male siblings 69 and 66-years-old with B-cell chronic lymphocytic leukemia (B-CLL).
  • One brother (patient 1, 69 years of age) showed deletion of the 13q14 region, this alteration was associated with low CD38 expression, both predicting a favourable prognosis.
  • Thus, we found the variability of these parameters described in B-CLL even in the familial form of the disease.
  • [MeSH-major] ADP-ribosyl Cyclase / biosynthesis. Antigens, CD / biosynthesis. Chromosome Aberrations. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621833.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Membrane Glycoproteins; EC 3.2.2.5 / ADP-ribosyl Cyclase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


9. Zenz T, Benner A, Stilgenbauer S: MDM2 promotor polymorphism and disease characteristics in CLL. Leuk Res; 2010 May;34(5):578-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDM2 promotor polymorphism and disease characteristics in CLL.
  • [MeSH-major] Genetic Predisposition to Disease. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Proto-Oncogene Proteins c-mdm2 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Res. 2010 Mar;34(3):335-9 [19573916.001]
  • (PMID = 19709747.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] England
  • [Chemical-registry-number] EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


10. Hashimoto Y, Tsukamoto N, Nakahashi H, Yokohama A, Saitoh T, Handa H, Matsushima T, Murakami H, Nojima Y, Karasawa M: Hairy cell leukemia-related disorders consistently show low CD27 expression. Pathol Oncol Res; 2009 Dec;15(4):615-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hairy cell leukemia-related disorders consistently show low CD27 expression.
  • In Japan, typical hairy cell leukemia (HCL) is rare, and HCL-Japanese variant (HCL-JV) is more common.
  • Hairy B-cell lymphoproliferative disorder (HBLD) is another unusual disorder of polyclonal B-lymphocytosis of hairy cell appearance.
  • As compared with other B-cell lymphoproliferative disorders, CD27 expression on B cells was significantly lower in all patients, ranging from 0.3% to 23.4%.
  • Our results suggest that low CD27 expression may be a distinct feature of these HCL-related disorders.
  • [MeSH-major] Antigens, CD27 / metabolism. Leukemia, Hairy Cell / ethnology. Leukemia, Hairy Cell / metabolism. Lymphoproliferative Disorders / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers / metabolism. Case-Control Studies. Female. HLA-DR Antigens / metabolism. HLA-DRB1 Chains. Humans. Immunoglobulin Heavy Chains / metabolism. Japan. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma / metabolism. Lymphoma, Follicular / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):437-48 [16723990.001]
  • [Cites] Leuk Res. 2002 Sep;26(9):809-15 [12127555.001]
  • [Cites] Tissue Antigens. 1994 Sep;44(3):166-73 [7839349.001]
  • [Cites] Blood. 1997 Sep 1;90(5):2110-3 [9292552.001]
  • [Cites] Rinsho Ketsueki. 2007 Aug;48(8):647-51 [17867302.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):223-34 [12542479.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1855-8 [12685844.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3556-65 [7540066.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3430-6 [8241510.001]
  • [Cites] Rinsho Ketsueki. 1998 Jul;39(7):493-8 [9750456.001]
  • [Cites] Leukemia. 1993 Feb;7(2):181-6 [8426471.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):783-91 [16157685.001]
  • [Cites] Haematologica. 2005 Feb;90(2):266-8 [15710587.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2008-14 [9058722.001]
  • [Cites] Leuk Lymphoma. 1996 Jan;20(3-4):275-9 [8624467.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1729-32 [15356640.001]
  • [Cites] Immunol Today. 2000 May;21(5):204-6 [10782048.001]
  • [Cites] Am J Hematol. 1996 Feb;51(2):141-6 [8579055.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):171-8 [9576198.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):41-56 [12670464.001]
  • [Cites] Rinsho Ketsueki. 2004 Apr;45(4):312-5 [15168448.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):272-6 [16159662.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):36-43 [12670329.001]
  • [Cites] N Engl J Med. 1982 Jul 22;307(4):232-6 [6979709.001]
  • (PMID = 19301150.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Biomarkers; 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains; 0 / HLA-DRB1*04 antigen; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


11. Wu SJ, Huang SY, Lin CT, Lin YJ, Chang CJ, Tien HF: The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood; 2010 Nov 25;116(22):4430-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect.
  • The incidence of chronic lymphocytic leukemia (CLL) in Taiwan is markedly lower than that in Western countries, but we have seen a drastically increasing trend.
  • We explored this distinct incidence trend of CLL for Taiwanese.
  • The epidemiologic data of CLL for Taiwanese and Caucasian Americans during 1986 to 2005 were obtained from the Taiwan National Cancer Registry and Surveillance, Epidemiology, and End Results Program, respectively.
  • Although there was a weak period effect corresponding to the increased applications of immunophenotyping in 1991 to 1995 in Taiwan, evidences suggested that the age-adjusted incidence rate of CLL for Taiwanese was continuously increasing during the 20-year period while that for Caucasian Americans remained steady.
  • We conclude that, in addition to the ethnic difference of incidence, there is distinct increasing incidence trend of CLL in Taiwan.
  • The strong birth-cohort effect underlying this increasing trend indicates that lifestyles and environmental factors may play a role in the development of CLL for Taiwanese.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20713960.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Liu L, Yang C, Herzog C, Seth R, Kaushal GP: Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol; 2010 Jan 15;79(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate the effect of proteasome inhibitors in mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-exposed renal tubular epithelial cells (LLC-PK(1) cells) and in a model of cisplatin nephrotoxicity.
  • Downregulation of Mcl-1 by small interfering RNA promoted Bax activation and cytochrome c and AIF release, suggesting that cisplatin-induced Mcl-1 depletion and associated Bax activation are involved in the release of AIF.
  • [MeSH-minor] Animals. Blotting, Western. Immunoprecipitation. LLC-PK1 Cells. Male. Mice. Mice, Inbred C57BL. Swine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699182.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Novaretti MC, Domingues AE, Manhani R, Pinto EM, Dorlhiac-Llacer PE, Chamone DA: ABO genotyping in leukemia patients reveals new ABO variant alleles. Genet Mol Res; 2008;7(1):87-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABO genotyping in leukemia patients reveals new ABO variant alleles.
  • The aim of the present study was to perform ABO genotyping in patients with leukemia.
  • Blood samples were collected from 108 Brazilian patients with chronic myeloid leukemia (N = 69), chronic lymphoid leukemia (N = 13), acute myeloid leukemia (N = 15), and acute lymphoid leukemia (N = 11).
  • We identified 22 new ABO*variants in the coding region of the ABO gene in 25 individuals with leukemia (23.2%).
  • The majority of ABO variants was detected in O alleles (15/60.0%).
  • Elucidation of the diversity of this gene in leukemia and in other diseases is important for the determination of the effect of changes in an amino acid residue on the specificity and activity of ABO glycosyltransferases and their function.
  • In conclusion, this is the first report of a large number of patients with leukemia genotyped for ABO.
  • The findings of this study indicate that there is a high level of recombinant activity in the ABO gene in leukemia patients, revealing new ABO variants.
  • [MeSH-major] ABO Blood-Group System / genetics. Alleles. Genetic Variation. Leukemia / blood

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273824.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 9007-49-2 / DNA
  •  go-up   go-down


14. Gintowt AA, Germer JJ, Mitchell PS, Yao JD: Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit. J Clin Virol; 2005 Oct;34(2):155-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The current manual sample processing method recommended for use with the TRUGENE HBV Genotyping Kit (TRUGENE HBV; Bayer HealthCare LLC, Tarrytown, NY) is labor-intensive and may be prone to specimen cross-contamination.
  • Performance of TRUGENE HBV used in conjunction with MP sample processing was evaluated further using 22 clinical serum specimens containing low titers of HBV DNA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023890.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


15. Rhyu DY, Kang KS, Sekiya M, Tanaka T, Park JC, Yokozawa T: Active compounds isolated from traditional Chinese prescription Wen-Pi-Tang protecting against peroxynitrite-induced LLC-PK(1) cell damage. Am J Chin Med; 2008;36(4):761-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active compounds isolated from traditional Chinese prescription Wen-Pi-Tang protecting against peroxynitrite-induced LLC-PK(1) cell damage.
  • Wen-Pi-Tang, a traditional Chinese prescription, has been widely used for the treatment of patients with moderate chronic renal failure in China.
  • Although the protective effect of Wen-Pi-Tang on peroxynitrite (ONOO(-))-induced renal tubular epithelial LLC-PK(1) cell damage was elucidated in our previous research, the active components of Wen-Pi-Tang have not yet been fully clarified.
  • Therefore, the major bioactivity of Wen-Pi-Tang against ONOO(-)-induced cytotoxicity in LLC-PK(1) cells was thought to be mediated by (+)-catechin.
  • Although we cannot disregard the synergetic effect of various components in Wen-Pi-Tang, (+)-catechin is a major active compound protecting against ONOO(-)-induced LLC-PK(1) cell damage and may be used as an index to qualify the ONOO(-)-inhibitory activity of Wen-Pi-Tang extract.
  • [MeSH-minor] Animals. Cell Line. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Free Radicals / metabolism. Molsidomine / analogs & derivatives. Molsidomine / pharmacology. Nitric Oxide Donors / pharmacology. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711772.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Free Radicals; 0 / Nitric Oxide Donors; 0 / wen-pi-tang; 14691-52-2 / Peroxynitrous Acid; 5O5U71P6VQ / linsidomine; 8R1V1STN48 / Catechin; D46583G77X / Molsidomine
  •  go-up   go-down


16. Mailloux AW, Clark AM, Young MR: NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells. Int J Cancer; 2010 Dec 1;127(11):2598-611
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies demonstrated that NK-dependant increases in CCL22 secretion selectively recruit Tregs toward murine lungs bearing Lewis Lung Carcinoma (LLC).
  • To extend the in vitro studies, the present studies utilized in vivo depletion of NK cells to ascertain the contribution of NK-derived CCL22 toward total CCL22 and subsequent Treg levels in both normal and LLC-bearing lungs.
  • However, NK depletion had the unexpected effect of increasing both CCL22 secretion and Treg levels in the lungs of NK-depleted LLC-bearing mice.
  • Flow cytometry and a series of both immunomagnetic and FACS isolations were used to identify the CCL22-producing cellular fractions in LLC-bearing lungs.
  • A novel CD11b(+)CD11c(+) cell population was identified that accumulates in large numbers in NK-depleted LLC-bearing lung tissue.
  • These CD11b(+)CD11c(+) cells secreted large amounts of CCL22 that may overcompensate for the loss of NK-derived CCL22 in the lungs of NK-depleted LLC-bearing mice.
  • Taken together, these data suggest that NK cells play both a positive and negative role in the regulation of CCL22 secretion and, in turn, the recruitment of Tregs toward LLC-bearing lungs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Feb 21;191(4):661-8 [10684858.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):2753-65 [19234170.001]
  • [Cites] Int Immunol. 2001 Apr;13(4):459-63 [11282985.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):531-7 [11310838.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2342-8 [12805336.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Semin Immunol. 2004 Apr;16(2):89-98 [15036232.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Reticuloendothel Soc. 1979 Jun;25(6):623-33 [385867.001]
  • [Cites] Boll Ist Sieroter Milan. 1985;64(1):25-34 [3859302.001]
  • [Cites] J Natl Cancer Inst. 1986 Apr;76(4):745-50 [3457207.001]
  • [Cites] J Natl Cancer Inst. 1986 Dec;77(6):1255-60 [3491925.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):275-82 [9568645.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):5027-38 [9794440.001]
  • [Cites] Diabetes. 2005 Feb;54(2):434-42 [15677501.001]
  • [Cites] J Immunol. 2009 Dec 15;183(12):8044-53 [19933856.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6169-76 [16237114.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5716-22 [16740709.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):123-31 [17522861.001]
  • [Cites] Blood. 2008 Jan 15;111(2):761-6 [17967942.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2286-93 [18224687.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1733-41 [11238115.001]
  • (PMID = 20198623.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA8566; United States / NIDCR NIH HHS / DE / R01 DE018168-02; United States / NCI NIH HHS / CA / 1R01CA128837; United States / NCI NIH HHS / CA / R01 CA085266-06; United States / NCI NIH HHS / CA / R01 CA085266; United States / NIDCR NIH HHS / DE / R01DE018168; United States / NIDCR NIH HHS / DE / R01 DE018168; United States / NCI NIH HHS / CA / CA128837-01A2; United States / NCI NIH HHS / CA / R01 CA128837; United States / NCI NIH HHS / CA / R01 CA128837-01A2; United States / NIDCR NIH HHS / DE / DE018168-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD11c; 0 / CCL22 protein, human; 0 / Chemokine CCL22; 37758-47-7 / G(M1) Ganglioside; 71012-19-6 / asialo GM1 ganglioside
  • [Other-IDs] NLM/ NIHMS189166; NLM/ PMC2947555
  •  go-up   go-down


17. García-Sanz R, Ocio EM: Novel treatment regimens for Waldenström's macroglobulinemia. Expert Rev Hematol; 2010 Jun;3(3):339-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder defined by bone marrow infiltration by lymphoplasmacytic cells as defined by the current classification systems.
  • According to its transition situation between mutated chronic lymphocytic leukemia and multiple myeloma, several new therapeutic alternatives have been proposed for this entity based on the experience with these two well-known conditions together with the highly singular data provided by preclinical models.
  • Here we review the most recent results reported for the use of new combinations and new drugs in patients with WM at different stages of the disease.
  • [MeSH-minor] B-Lymphocytes / enzymology. B-Lymphocytes / immunology. Drug Administration Schedule. Humans. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082984.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antibodies, Monoclonal; 0 / Antioxidants; 0 / Histone Deacetylase Inhibitors; 0 / Immunologic Factors; 0 / Protease Inhibitors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


18. Dimeski G, Bird R: Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis. Clin Chem Lab Med; 2009;47(7):880-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis.

  • MedlinePlus Health Information. consumer health - Potassium.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575549.001).
  • [ISSN] 1437-4331
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gases; RWP5GA015D / Potassium
  •  go-up   go-down


19. Coscia G, Vaccara E, Corvisiero R, Cavazzani P, Ruggieri FG, Taccini G: Fractionated stereotactic radiotherapy: a method to evaluate geometric and dosimetric uncertainties using radiochromic films. Med Phys; 2009 Jul;36(7):2870-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The comparison between the dose distributions measured on films and computed by TPS, after a precise image registration procedure performed by a commercial piece of software (FILMQA, 3cognition LLC (Division of ISP), Wayne, NJ), allowed the authors to measure the repositioning errors, obtaining about 0.5 mm in case of central spherical PTV and about 1.5 mm in case of peripheral irregular PTV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673186.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Reid-Nicholson M, Kavuri S, Ustun C, Crawford J, Nayak-Kapoor A, Ramalingam P: Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation. Cancer; 2008 Oct 25;114(5):333-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin lymphoma that was once believed to occur primarily in the oral cavity of human immunodeficiency virus-positive individuals.
  • The presence of the following was evaluated: cellularity, plasmablastic cells, background necrosis (BN), single-cell necrosis (SCN), lymphoglandular bodies (LGB), tingible-body macrophages (TBM), 3-dimensional clusters/sheets, and cytoplasmic vacuoles.
  • Two patients had the acquired immunodeficiency syndrome and 3 had second non-PBL related malignancies including endometrial carcinoma, lung adenocarcinoma, and small lymphocytic lymphoma.
  • However, although these findings may suggest PBL, a definitive diagnosis requires adjunctive studies including immunohistochemistry and flow cytometry.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683216.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Amagase H, Nance DM: A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) Juice, GoChi. J Altern Complement Med; 2008 May;14(4):403-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) Juice, GoChi.
  • BACKGROUND: This randomized, double-blind, placebo-controlled clinical trial is the first study reported from outside China that has examined the general effects of the orally consumed goji berry, Lycium barbarum, as a standardized juice (GoChi; FreeLife International LLC, Phoenix, AZ) to healthy adults for 14 days.
  • METHODS: Based upon the medicinal properties of Lycium barbarum in traditional Asian medicine, we examined by questionnaire subjective ratings (0-5) of general feelings of well-being, neurologic/psychologic traits, gastrointestinal, musculoskeletal, and cardiovascular complaints as well as any adverse effects.
  • CONCLUSIONS: These results clearly indicate that daily consumption of GoChi for 14 days increases subjective feelings of general well-being, and improves neurologic/psychologic performance and gastrointestinal functions.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447631.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 0 / Plant Extracts
  •  go-up   go-down


22. John R, Liao K, Lietz K, Kamdar F, Colvin-Adams M, Boyle A, Miller L, Joyce L: Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg; 2007 Aug;134(2):351-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We review our experience with the use of the CentriMag (Levitronix LLC, Waltham, Mass) circulatory support system in such patients whose neurologic status was uncertain.
  • Thus, for our 12 study patients, long-term survival was 75% at 1 month and 62.5% at 1 year.
  • By using this strategy, we avoided the urgent placement of expensive long-term ventricular assist devices in hemodynamically unstable patients with multisystem organ failure whose neurologic status was uncertain until end-organ recovery and excellent hemodynamic stability were achieved with the relatively inexpensive short-term CentriMag circulatory support system.
  • [MeSH-minor] Acute Disease. Analysis of Variance. Decision Making. Heart Transplantation / statistics & numerical data. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Cardiovasc Surg. 2008 Mar;135(3):717; author reply 717-8 [18329513.001]
  • (PMID = 17662772.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Peeters MY, Prins SA, Knibbe CA, Dejongh J, Mathôt RA, Warris C, van Schaik RH, Tibboel D, Danhof M: Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology; 2006 Dec;105(6):1135-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Population pharmacokinetic and pharmacodynamic modeling was performed using NONMEM V (GloboMax LLC, Hanover, MD).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Midazolam .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122576.001).
  • [ISSN] 0003-3022
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives; R60L0SM5BC / Midazolam
  •  go-up   go-down


24. Li Y, Zhu Z: Monoclonal antibody-based therapeutics for leukemia. Expert Opin Biol Ther; 2007 Mar;7(3):319-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody-based therapeutics for leukemia.
  • Alemtuzumab is approved for B cell chronic lymphocytic leukemia; rituximab, an anti-CD20 antibody approved for the treatment of B cell non-Hodgkin's lymphoma, is being tested in patients with chronic lymphocytic leukemia; and gemtuzumab ozogamicin is marketed for relapsed acute myelogenous leukemia in patients of > 60 years of age.
  • This article discusses the general aspects and mechanisms of action of therapeutic mAbs, and highlights the development of antibody-based therapies in leukemia.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Humans

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309324.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal
  • [Number-of-references] 94
  •  go-up   go-down


25. Ticchioni M, Essafi M, Jeandel PY, Davi F, Cassuto JP, Deckert M, Bernard A: Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene; 2007 Nov 1;26(50):7081-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a.
  • B-chronic lymphocytic leukemia (B-CLL) cell is characterized by the accumulation of long-lived CD5+ B lymphocytes, whose survival in vivo is in part dependent on exogenous factors such as cytokines and/or extracellular matrix proteins.
  • Homeostatic chemokines are critical mediators of lymphoid cell trafficking.
  • However, how they function in cell signaling and survival remains ill-defined.
  • In this study, we have investigated the role of the homeostatic chemokines, CXCL12, CCL21, CCL19 and CXCL13, in B-CLL cell survival.
  • Using primary leukemic cells isolated from 26 patients, we observed that each chemokine enhances cell survival.
  • Moreover, using a constitutively active mutated form of FOXO3a or siRNAs against FOXO3a in transfection experiments performed in primary B-CLL cells, we directly demonstrated the critical role of FOXO3a in both spontaneous and chemokine-induced B-CLL cell survival.
  • Overall, our data support the notion that homeostatic chemokines contribute to B-CLL resistance to cell death through inactivation of the transcription factor FOXO3a, which may represent a novel therapeutic target in this hematopoietic malignancy.
  • [MeSH-major] Chemokines / physiology. Forkhead Transcription Factors / antagonists & inhibitors. Homeostasis / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Apoptosis / genetics. Apoptosis / immunology. Cell Death / genetics. Cell Death / immunology. Cell Survival / immunology. Female. Humans. Male. Middle Aged. Transcriptional Activation / genetics. Transcriptional Activation / immunology


26. Reichardt VL, Brossart P: Current status of vaccination therapy for leukemias. Curr Hematol Rep; 2005 Jan;4(1):73-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of vaccination therapy for leukemias.
  • Acute and chronic leukemias are common diseases in the clinical practice but few vaccination protocols have found their way to phase I trials in leukemias.
  • Therapeutic vaccination protocols share the goal of inducing or augmenting leukemia-specific immune responses in the tumor-bearing host in order to potentially achieve therapeutical benefit in these otherwise fatal diseases.
  • Major interest has been drawn to the use of dendritic cell (DC-based immunotherapy protocols relying on the unique properties of these most powerful antigen-presenting cells.
  • With the bcr-abl oncogene a target of specific immunotherapy has been determined in chronic myelogenous leukemia (CML), while there is a limited information on leukemia-specific tumor antigens in acute myelogenous and lymphoblastic leukemias.
  • This review will focus on immunotherapy development in acute and chronic leukemias and will discuss published clinical trials in acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and CML.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Leukemia / therapy. Vaccination
  • [MeSH-minor] Acute Disease. Clinical Trials as Topic. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610663.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 29
  •  go-up   go-down


27. Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J: Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant; 2005 Nov;36(9):825-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.
  • In all, 30 patients with CLL proceeded to myeloablative allogeneic BMT using related (n=20, 67%) or unrelated (n=10) donors, at the Princess Margaret Hospital (Toronto) (n=20) or the Leukemia/BMT Program of BC (Vancouver) (n=10), from 1989 to 2001.
  • Median (range) interval from diagnosis to BMT was 4.8 (0.3-13) years, median number of prior therapies was three and median age 48 years.
  • Actuarial overall (OS) and event-free survival (EFS) at 5 years is 39% (OS 48% for related donor and 20% for unrelated donor BMT); cumulative incidence of nonrelapse mortality (NRM) and relapse is 47 and 19%, respectively.
  • Both acute (RR=0.008, P=0.01) and chronic (RR=0.006, P=0.02) Graft-versus-host disease (GVHD) were associated with markedly decreased risk of relapse.
  • Patients receiving grafts from unrelated donors had increased NRM (RR=3.6, P=0.02) and decreased OS (RR of death=3.4, P=0.002).
  • Allogeneic BMT has resulted in long-term EFS in approximately 40% of patients with CLL.
  • There is evidence for a strong graft-versus-leukemia effect associated with acute and chronic GVHD, resulting in near complete protection from relapse.
  • [MeSH-major] Bone Marrow Transplantation. Graft vs Host Disease / mortality. Graft vs Leukemia Effect. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Tissue Donors
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Histocompatibility Testing / methods. Humans. Male. Middle Aged. Recurrence. Remission Induction / methods. Retrospective Studies. Transplantation Conditioning / methods. Transplantation, Homologous. Whole-Body Irradiation / methods


28. Rassenti LZ, Kipps TJ: Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom; 2006 Jul 15;70(4):209-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.
  • [MeSH-major] Antigens, CD38 / analysis. Biomarkers, Tumor / analysis. Flow Cytometry / methods. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. ZAP-70 Protein-Tyrosine Kinase / analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906583.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA81534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38
  • [Number-of-references] 44
  •  go-up   go-down


29. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One; 2009;4(11):e7826
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.
  • BACKGROUND: Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in the progress of adult leukemia.
  • The role of miRNAs in pediatric leukemia still needs to be established.
  • The purpose of this study was to investigate the aberrantly expressed miRNAs in pediatric acute leukemia and demonstrate miRNA patterns that are pediatric-specific and prognostic parameter-associated.
  • The most highly expressed miRNAs in pediatric ALL were miR-34a, miR-128a, miR-128b, and miR-146a, while the highly expressed miRNAs in pediatric AML were miR-100, miR-125b, miR-335, miR-146a, and miR-99a, which are significantly different from those reported for adult CLL and AML. miR-125b and miR-126 may serve as favorable prognosticators for M3 and M2 patients, respectively.
  • CONCLUSIONS/SIGNIFICANCE: There are existing pediatric-associated and prognostic parameter-associated miRNAs that are independent of cell lineage and could provide therapeutic direction for individual risk-adapted therapy for pediatric leukemia patients.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Leukemia / diagnosis. Leukemia / pathology. MicroRNAs

  • MedlinePlus Health Information. consumer health - Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] J Pediatr (Rio J). 2003 Mar-Apr;79(2):149-58 [14502336.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):338-45 [15735639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1768-71 [16251533.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):167-73 [16616063.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2825-32 [18089852.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50 [18308931.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Dev Biol. 1999 Dec 15;216(2):671-80 [10642801.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):179-81 [12525506.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • (PMID = 19915715.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2773830
  •  go-up   go-down


30. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F, Messina M, Maggio R, Peragine N, Santangelo S, Mauro FR, Landgraf P, Tuschl T, Weir DB, Chien M, Russo JJ, Ju J, Sheridan R, Sander C, Zavolan M, Guarini A, Foà R, Macino G: Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood; 2007 Jun 1;109(11):4944-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia.
  • MicroRNAs (miRNAs) are a novel class of small noncoding RNAs that modulate the expression of genes at the posttranscriptional level.
  • These small molecules have been shown to be involved in cancer, apoptosis, and cell metabolism.
  • In the present study we provide an informative profile of the expression of miRNAs in primary chronic lymphocytic leukemia (CLL) cells using 2 independent and quantitative methods: miRNA cloning and quantitative real-time-polymerase chain reaction (qRT-PCR) of mature miRNAs.
  • Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL.
  • In summary, the results of this study offer for the first time a comprehensive and quantitative profile of miRNA expression in CLL and their healthy counterpart, suggesting that miRNAs could play a primary role in the disease itself.
  • [MeSH-major] Gene Expression Profiling. Genetic Techniques. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. MicroRNAs / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327404.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / MicroRNAs; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


31. Kumar A, Balkrishna A: To study the effect of the sequence of seven pranayama by Swami Ramdev on gene expression in leukaemia patients and rapid interpretation of gene expression. J Clin Pathol; 2009 Nov;62(11):1052-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] To study the effect of the sequence of seven pranayama by Swami Ramdev on gene expression in leukaemia patients and rapid interpretation of gene expression.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Yoga

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861570.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


32. Sweeney N, Gallagher WM, Müller-Bunz H, Pampillón C, Strohfeldt K, Tacke M: Heteroaryl substituted titanocenes as potential anti-cancer drugs. J Inorg Biochem; 2006 Sep;100(9):1479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When titanocenes 3a-c were tested against pig kidney (LLC-PK) cells inhibitory concentrations (IC(50)) of 1.6x10(-4)M, 1.5x10(-4)M and 9.1x10(-4)M, respectively, were observed.
  • These values represent improved cytotoxicity against LLC-PK, when compared to their corresponding ansa substituted analogues and also in comparison to unsubstituted titanocene dichloride.
  • [MeSH-minor] Animals. Cell Line. Cell Survival. Drug Evaluation, Preclinical. Molecular Conformation. Molecular Structure. Swine

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764931.001).
  • [ISSN] 0162-0134
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organometallic Compounds; 1271-29-0 / titanocene
  •  go-up   go-down


33. Kalita J, Patel NS, Misra UK: Magnetic resonance imaging may simulate progressive multifocal leucoencephalopathy in a patient with chronic lymphocytic leukemia after fludarabine therapy. Ann Indian Acad Neurol; 2008 Apr;11(2):114-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging may simulate progressive multifocal leucoencephalopathy in a patient with chronic lymphocytic leukemia after fludarabine therapy.
  • A 60-year-old male with chronic lymphatic leukemia (CLL) after 6 months of fludarabine therapy was admitted with status epilepticus and developed left hemiplegia.
  • We suggest the possible role of fludarabine in producing PML-like lesions in patients with Chronic Lymphocytic Leukemia (CLL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1992 Nov 7;340(8828):1135 [1359217.001]
  • [Cites] Lancet. 1994 Dec 24-31;344(8939-8940):1780 [7997036.001]
  • [Cites] Neurol Neurochir Pol. 1993 Nov-Dec;27(6):905-12 [8164786.001]
  • [Cites] Brain. 1958 Mar;81(1):93-111 [13523006.001]
  • [Cites] Radiology. 1993 Apr;187(1):233-40 [8451420.001]
  • [Cites] J Neurol Sci. 1997 Mar 20;147(1):63-72 [9094062.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):569-71 [11032602.001]
  • [Cites] Leukemia. 1994 Feb;8(2):318-21 [8309257.001]
  • (PMID = 19893650.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2771959
  • [Keywords] NOTNLM ; Progressive multifocal leucoencephalopathy / chronic lymphocytic leukemia / fludarabine
  •  go-up   go-down


34. Sekikawa T, Takahara S, Suzuki H, Takeda N, Yamada H, Horiguchi-Yamada J: Diffuse large B-cell lymphoma arising independently to lymphoplasmacytic lymphoma: a case of two lymphomas. Eur J Haematol; 2007 Mar;78(3):264-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma arising independently to lymphoplasmacytic lymphoma: a case of two lymphomas.
  • Richter's syndrome occurs in 5-10% of patients with chronic lymphocytic leukemia, either by transformation of the primary neoplastic lymphocyte, or as a distinct B-cell neoplasm.
  • We report a Japanese patient with lymphoplasmacytic lymphoma in whom a diffuse large B-cell lymphoma developed after treatment with rituximab.
  • Molecular examination on immunoglobulin VH genes revealed that the lymphomas had arisen in two separate clones.
  • We reviewed clinical case reports in literature, and found 30-40% of cases with Richter's syndrome and composite lymphoma had a second B-cell lymphoma of a different origin.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253969.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger
  • [Number-of-references] 32
  •  go-up   go-down


35. Janel A, Bonnemoy S, Mathevon T, Sapin V: [Pseudo-hyperkalaemia and chronical lymphoïd leukaemia: about one observation]. Ann Biol Clin (Paris); 2009 May-Jun;67(3):338-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudo-hyperkalaemia and chronical lymphoïd leukaemia: about one observation].
  • [Transliterated title] Pseudo-hyperkaliémie et leucémie lymphoïde chronique: à propos d'un cas.
  • This gap is explained by the high leukocytosis of this patient (561 G/L) within a context of chronic lymphocytic leukemia as well as by the fragility of these cells revealed by specific rules for samples transport between the clinical departments and the central laboratory.
  • [MeSH-major] Heart Failure / etiology. Hyperkalemia / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19411237.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] RWP5GA015D / Potassium
  •  go-up   go-down


36. Nunes P, Hasler U, McKee M, Lu HA, Bouley R, Brown D: A fluorimetry-based ssYFP secretion assay to monitor vasopressin-induced exocytosis in LLC-PK1 cells expressing aquaporin-2. Am J Physiol Cell Physiol; 2008 Dec;295(6):C1476-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fluorimetry-based ssYFP secretion assay to monitor vasopressin-induced exocytosis in LLC-PK1 cells expressing aquaporin-2.
  • Vasopressin (VP)-induced exocytosis was dissected in native and aquaporin-2 (AQP2)-expressing renal LLC-PK(1) cells by a fluorimetric exocytosis assay based on soluble secreted yellow fluorescent protein (ssYFP).
  • Fluorimetry and Western blot analysis demonstrated similar constitutive ssYFP secretion in native LLC-PK(1) and AQP2-expressing cells.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2005 Jun;288(6):F1103-12 [15644488.001]
  • [Cites] J Biol Chem. 2008 Sep 26;283(39):26643-61 [18664568.001]
  • [Cites] Mol Cell Proteomics. 2005 Aug;4(8):1095-106 [15905145.001]
  • [Cites] Histochem Cell Biol. 2005 Jul;124(1):1-12 [16049696.001]
  • [Cites] J Am Soc Nephrol. 2005 Oct;16(10):2881-9 [16093449.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1113-25 [16186257.001]
  • [Cites] Traffic. 2005 Dec;6(12):1142-56 [16262725.001]
  • [Cites] Nephrol Dial Transplant. 2000;15 Suppl 6:21-2 [11143977.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Dec;281(6):F1092-101 [11704560.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):205-44 [11773613.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10379-86 [11782489.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Jun;282(6):F998-1011 [11997316.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):1101-7 [12374804.001]
  • [Cites] EMBO Rep. 2003 Jan;4(1):88-93 [12524527.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 May;284(5):F893-901 [12676734.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Oct;285(4):C750-62 [12801889.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Feb;286(2):F233-43 [14519593.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32 [15040445.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13368-73 [15326289.001]
  • [Cites] Mol Cell Biol. 1985 Dec;5(12):3610-6 [3915782.001]
  • [Cites] Am J Physiol. 1993 Aug;265(2 Pt 2):F214-24 [8396343.001]
  • [Cites] Experientia. 1994 Nov 30;50(11-12):1012-20 [7988659.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7212-6 [7543677.001]
  • [Cites] EMBO J. 1996 Feb 1;15(3):510-9 [8599934.001]
  • [Cites] J Biol Chem. 1997 Jun 6;272(23):14800-4 [9169447.001]
  • [Cites] Am J Physiol. 1997 Jun;272(6 Pt 2):F817-22 [9227644.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Feb;278(2):F317-26 [10662736.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Mar;278(3):F388-94 [10710543.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jan;278(1):F29-42 [10644653.001]
  • [Cites] J Cell Sci. 2000 Jun;113 ( Pt 11):1985-92 [10806109.001]
  • [Cites] J Clin Invest. 2000 Nov;106(9):1115-26 [11067864.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36839-46 [10973964.001]
  • [Cites] Plant Cell Physiol. 2000 Sep;41(9):993-1001 [11100771.001]
  • [Cites] Nature. 1997 Sep 4;389(6646):81-5 [9288971.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):133-42 [9352218.001]
  • [Cites] Curr Opin Neurobiol. 1997 Oct;7(5):631-9 [9384543.001]
  • [Cites] J Membr Biol. 1998 Jan 15;161(2):141-9 [9435270.001]
  • [Cites] Biochem J. 1998 Apr 15;331 ( Pt 2):669-75 [9531511.001]
  • [Cites] J Cell Biol. 1998 Dec 14;143(6):1485-503 [9852146.001]
  • [Cites] J Am Soc Nephrol. 1999 Jul;10(7):1416-29 [10405197.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46969-80 [15319442.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 May;288(5):F930-8 [15625084.001]
  • [Cites] Endocrinology. 2005 Dec;146(12):5063-70 [16150901.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jan;290(1):F177-87 [15985652.001]
  • [Cites] Biol Cell. 2006 Apr;98(4):215-32 [16563128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7159-64 [16641100.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1276-86 [16418206.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jul;291(1):F246-53 [16449354.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Oct;291(4):F882-90 [16684923.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:439-55 [16824007.001]
  • [Cites] Traffic. 2007 Feb;8(2):110-23 [17156409.001]
  • [Cites] PLoS Comput Biol. 2007 Mar 23;3(3):e57 [17381238.001]
  • [Cites] Nat Rev Genet. 2007 Jul;8(7):533-43 [17572691.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1129-38 [17626240.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28721-32 [17636261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16696-701 [17940053.001]
  • [Cites] Neuron. 2007 Nov 21;56(4):657-69 [18031683.001]
  • [Cites] Semin Nephrol. 2008 May;28(3):266-78 [18519087.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2008 Sep;17(5):491-8 [18695390.001]
  • [Cites] J Cell Biol. 2008 Aug 11;182(3):587-601 [18678705.001]
  • [Cites] J Am Soc Nephrol. 2005 Jun;16(6):1571-82 [15843469.001]
  • (PMID = 18799651.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-38452; United States / NIDDK NIH HHS / DK / DK-43341; United States / NIDDK NIH HHS / DK / DK-57521; United States / NIDDK NIH HHS / DK / K08 DK-075940-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aquaporin 2; 0 / Luminescent Proteins; 11000-17-2 / Vasopressins
  • [Other-IDs] NLM/ PMC2603565
  •  go-up   go-down


37. Nabhan C: Frontline therapy for chronic lymphocytic leukemia: the dilemma continues. Clin Cancer Res; 2008 Jul 1;14(13):4353
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Cancer Res. 2008 Jan 1;14(1):155-61 [18172266.001]
  • (PMID = 18594019.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


38. Schwemmlein M, Stieglmaier J, Kellner C, Peipp M, Saul D, Oduncu F, Emmerich B, Stockmeyer B, Lang P, Beck JD, Fey GH: A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Leukemia; 2007 Jul;21(7):1405-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is present at high surface density on chronic B-lymphocytic leukemia (B-CLL) cells and cells of other B-cell malignancies, and is a prime target for therapy with antibody-derived agents.
  • Here we report the design of a monovalent immunotoxin consisting of a CD19-specific single-chain Fv antibody fragment fused to a derivative of Pseudomonas Exotoxin A.
  • This fusion protein induced efficient antigen-restricted apoptosis of several human leukemia- and lymphoma-derived cell lines including Nalm-6, which it eliminated at an effective concentration (EC(50)) of 2.5 nM.
  • The agent displayed synergistic toxicity when used in combination with valproic acid and cyclosporin A in cell-culture assays.
  • It induced apoptosis of primary malignant cells in 12/12 samples from B-CLL patients, including patients responding poorly to fludarabine, and of cells from one pediatric acute lymphoblastic leukemia patient.
  • [MeSH-major] Antigens, CD19 / drug effects. Apoptosis / drug effects. Immunotoxins / pharmacology. Leukemia, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495978.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Exotoxins; 0 / Immunoglobulin Fragments; 0 / Immunotoxins; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


39. Zhuang J, Hawkins SF, Glenn MA, Lin K, Johnson GG, Carter A, Cawley JC, Pettitt AR: Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica; 2010 Jan;95(1):110-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition.
  • BACKGROUND: The aims of the present study were to ascertain the activation status of Akt in the primary cells of chronic lymphocytic leukemia and to investigate the effects of specific Akt inhibition on chronic lymphocytic leukemia-cell survival.
  • The effects of two different, specific small-molecule inhibitors (A-443654 or Akti-1/2) or small interfering RNA on cell survival and downstream targets of Akt were assessed.
  • Apoptosis was determined by fluorescence-activated cell sorting analysis of phosphatidylserine exposure and by measurement of PARP cleavage.
  • RESULTS: Fully activated Akt was demonstrable in all chronic lymphocytic leukemia clones examined (n=26).
  • These results were validated with extensive controls and it was shown that a harsh method of cell extraction is needed for detection of the active enzyme.
  • Specific inhibition of Akt induced extensive apoptosis of chronic lymphocytic leukemia cells, which was associated with both a rapid loss of MCL1 through proteasomal degradation and increased expression of p53.
  • Moreover, the Akt inhibitors, at concentrations that induced extensive apoptosis in chronic lymphocytic leukemia cells, had little or no effect on normal peripheral blood mononuclear cells.
  • CONCLUSIONS: Chronic lymphocytic leukemia clones consistently contain activated Akt which plays a pivotal role in maintaining cell survival.
  • Inhibition of the Akt pathway may be of potential value as a novel therapeutic strategy in chronic lymphocytic leukemia.
  • [MeSH-major] Apoptosis / physiology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / physiology. Clone Cells. Enzyme Activation / drug effects. Enzyme Activation / physiology. Humans. Indazoles / therapeutic use. Indoles / therapeutic use

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Jan 15;111(2):846-55 [17928528.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2797-805 [18160669.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2366-74 [18381444.001]
  • [Cites] Blood. 2008 Jul 1;112(1):188-95 [18292287.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10853-8 [18664580.001]
  • [Cites] Leukemia. 2008 Jan;22(1):147-60 [17928881.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):2905-27 [10579998.001]
  • [Cites] Curr Biol. 2000 Oct 5;10(19):1201-4 [11050388.001]
  • [Cites] J Neurochem. 2001 Apr;77(1):94-102 [11279265.001]
  • [Cites] Blood. 2001 Aug 1;98(3):814-22 [11468183.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603 [11504915.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3050-7 [11698290.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] Annu Rev Biochem. 2001;70:535-602 [11395417.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2969-76 [11929788.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60 [12011454.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1404-9 [12149224.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3741-8 [12393602.001]
  • [Cites] Leukemia. 2003 Oct;17(10):1981-9 [14513048.001]
  • [Cites] Nature. 2004 Mar 18;428(6980):332-7 [15029198.001]
  • [Cites] Trends Biochem Sci. 2004 May;29(5):233-42 [15130559.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1391-400 [15175625.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1820-8 [8104532.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3452-9 [8241511.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] Blood. 1996 May 15;87(10):4382-9 [8639799.001]
  • [Cites] Blood. 1998 May 1;91(9):3379-89 [9558396.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15628-32 [9624155.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Br J Haematol. 2004 Nov;127(4):425-8 [15521919.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2365-72 [15621749.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Immunology. 2005 Apr;114(4):441-9 [15804279.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4820-7 [15728130.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):977-86 [15956255.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):992-1000 [16331885.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):749-60 [16543145.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1657-63 [16801400.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1668-76 [16645163.001]
  • [Cites] Clin Transl Oncol. 2006 Nov;8(11):805-11 [17134969.001]
  • [Cites] J Cell Biochem. 2007 Apr 1;100(5):1109-18 [17131382.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4564-71 [17495324.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):439-44 [17611497.001]
  • [Cites] Diabetes. 2007 Sep;56(9):2218-27 [17563061.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7081-91 [17496928.001]
  • [Cites] Biochem J. 2007 Dec 15;408(3):297-315 [17850214.001]
  • [Cites] Biochem J. 2005 Jan 15;385(Pt 2):399-408 [15456405.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):271-9 [15713898.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4497-503 [18662968.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3827-34 [18682598.001]
  • [CommentIn] Haematologica. 2010 Jan;95(1):12-5 [20065079.001]
  • (PMID = 19713228.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / A 443654; 0 / Indazoles; 0 / Indoles; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2805750
  •  go-up   go-down


40. Baseggio L, Gazzo S, Callet-Bauchu E, Traverse-Glehen A, Thieblemont C, Bryon PA, Magaud JP, Berger F, Felman P: An unusual case of indolent B-cell lymphoma with distinct chronic lymphocytic leukemia and marginal zone differentiation according to the site of involvement. Leuk Lymphoma; 2005 Sep;46(9):1369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of indolent B-cell lymphoma with distinct chronic lymphocytic leukemia and marginal zone differentiation according to the site of involvement.
  • The immunological profile of lymphoproliferative disorders is usually conserved whatever the involved site, thus allowing a reliable diagnosis from peripheral blood analysis, especially in small lymphocytic lymphoma/chronic lymphocytic lymphoma (SLL/CLL).
  • Here we present a case wherein the cytology and immunophenotype of blood specimen and bone marrow argue in favor of SLL/CLL with a typical Matutes score (5/5), whereas the cyto-histology and immunophenotype of spleen specimen led to the diagnosis of splenic marginal zone B-cell lymphoma (SMZL).
  • Whereas these data suggested the presence of 2 B-cell clones, the study of the mutational status of IgVH gene in blood and spleen demonstrated the presence of a single clone, which likely developed simultaneously along two distinct ways of differentiation according to the anatomic site suggesting here the predominant role of a micro-environmental factor in cell differentiation.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / blood. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Aged. Genes, Immunoglobulin. Humans. Immunophenotyping. Male. Mutation. Splenic Neoplasms / diagnosis


41. Kuramochi K, Matsui R, Matsubara Y, Nakai J, Sunoki T, Arai S, Nagata S, Nagahara Y, Mizushina Y, Ikekita M, Kobayashi S: Apoptosis-inducing effect of epolactaene derivatives on BALL-1 cells. Bioorg Med Chem; 2006 Apr 1;14(7):2151-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epolactaene, a neuritogenic compound in human neuroblastoma SH-SY5Y, induces apoptosis in a human leukemia B-cell line, BALL-1.
  • The alpha-acyl-alpha,beta-epoxy-gamma-lactam moiety as well as the hydrophobicity derived from the long alkyl side chain are both important for activity.
  • [MeSH-major] Apoptosis / drug effects. Leukemia, B-Cell / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Drug Screening Assays, Antitumor. Epoxy Compounds / chemical synthesis. Epoxy Compounds / chemistry. Epoxy Compounds / pharmacology. Humans. Hydrolysis. Molecular Structure. Polyenes / chemical synthesis. Polyenes / chemistry. Polyenes / pharmacology. Stereoisomerism. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298530.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Epoxy Compounds; 0 / Polyenes; 0 / epolactaene
  •  go-up   go-down


42. Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M: Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk; 2010 Feb;10(1):21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
  • Bendamustine is a novel bifunctional alkylating agent with promising activity in lymphoid malignancies and several solid tumors.
  • The use of this drug has been increasing since it has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia and rituximab-refractory indolent B-cell non-Hodgkin lymphoma, and is expected to increase further following anticipated European regulatory approval.
  • This report, representing the conclusions of that meeting, should provide guidance for the clinician until definitive dose-finding studies have been conducted.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Multiple Myeloma / drug therapy. Nitrogen Mustard Compounds / therapeutic use


43. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA, Fayad L, Medeiros LJ, Vega F: Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol; 2009 Oct;22(10):1312-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.
  • Dysregulation of the sonic hedgehog (SHH) signaling pathway has been shown in several cancer types, but has not been explored in diffuse large B-cell lymphoma.
  • We assessed 67 cases of diffuse large B-cell lymphoma for expression of SHH (ligand), GLI1, GLI2 and GLI3 (transcriptional effectors of SHH signaling), and the ATP-binding cassette (ABC)G2 (a downstream target of SHH signaling), using immunohistochemistry.
  • For comparison, we assessed the expression levels of these proteins in 28 cases of follicular lymphoma, 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, and 5 reactive lymph nodes.
  • In diffuse large B-cell lymphoma, SHH was expressed in 61 of 67 (91%) cases, GLI1 in 62 of 67 (93%), GLI2 in 41 of 56 (73%), and GLI3 in 22 of 56 (39%).
  • Patients with diffuse large B-cell lymphoma with high ABCG2 expression showed significantly shorter overall survival (P=0.031) and failure-free survival (P=0.029) compared with patients with tumors with low or no expression of ABCG2.
  • Diffuse large B-cell lymphomas expressed SHH, and GLI1, GLI2, and GLI3 more frequently and more intensely than cases of follicular lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • In conclusion, our data show that SHH signaling proteins and ABCG2 are aberrantly expressed in diffuse large B-cell lymphoma and that ABCG2 expression has prognostic implications.
  • These findings also provide evidence that dysregulation of the SHH pathway may be involved in the pathogenesis of diffuse large B-cell lymphoma.
  • [MeSH-major] ATP-Binding Cassette Transporters / analysis. Hedgehog Proteins / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, Follicular / chemistry. Lymphoma, Large B-Cell, Diffuse / chemistry. Neoplasm Proteins / analysis. Signal Transduction. Transcription Factors / analysis
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Kruppel-Like Transcription Factors / analysis. Lymph Nodes / chemistry. Male. Middle Aged. Nerve Tissue Proteins / analysis. Nuclear Proteins / analysis. Time Factors. Treatment Outcome. Up-Regulation. Zinc Finger Protein GLI1. Zinc Finger Protein Gli2. Zinc Finger Protein Gli3

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593328.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / GLI3 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / SHH protein, human; 0 / Transcription Factors; 0 / Zinc Finger Protein GLI1; 0 / Zinc Finger Protein Gli2; 0 / Zinc Finger Protein Gli3
  •  go-up   go-down


44. Lange D, Oeder C, Waltermann K, Mueller A, Oehme A, Rohrberg R, Marsch W, Fischer M: Bacillary angiomatosis. J Dtsch Dermatol Ges; 2009 Sep;7(9):767-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An infection with Bartonella henselae transmitted from domestic cats to humans by scratching normally leads to cat-scratch disease.
  • When the human host has severe immunosuppression or HIV infection, the potentially life-threatening disease bacillary angiomatosis can develop.
  • We considered a cutaneous infiltrate from his known chronic lymphocytic leukemia, Merkel cell carcinoma, cutaneous metastases of internal tumors, cutaneous sarcoidosis, mycobacterial infection and even atypical herpes simplex infection.
  • The correct diagnosis was proven histologically and by PCR.
  • Because of increasing numbers of immunosuppressed and HIV-positive patients, as well as an infection rate of 13% for B. henselae in domestic cats in Germany, one must be alert to the presence of bacillary angiomatosis.
  • [MeSH-major] Angiomatosis, Bacillary / diagnosis. Angiomatosis, Bacillary / microbiology. Bartonella henselae / isolation & purification. Cat-Scratch Disease / diagnosis. Cat-Scratch Disease / microbiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Herpes Simplex / diagnosis. Humans. Male. Skin Neoplasms / diagnosis


45. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC: Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood; 2010 Apr 01;115(13):2619-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
  • Chronic lymphocytic leukemia (CLL) involves a profound humoral immune defect and tumor-specific humoral tolerance that directly contribute to disease morbidity and mortality.
  • The immune-modulatory agent lenalidomide shows clinical activity in CLL, but its mechanism is poorly understood.
  • Here, we demonstrate that lenalidomide induces expression of functional CD154 antigen on CLL cells both in vitro and in vivo.
  • Importantly, CD154-positive CLL cells up-regulate BID, DR5, and p73, become sensitized to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis, and promote costimulatory activation of normal B cells to produce antibodies.
  • In CLL patients receiving lenalidomide, similar evidence of CD154 activation is observed including BID, DR5, and p73 induction and also development of anti-ROR1 tumor-directed antibodies.
  • Our data demonstrate that lenalidomide promotes CD154 expression on CLL cells with subsequent activation phenotype, and may therefore reverse the humoral immune defect observed in this disease.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Antineoplastic Agents / pharmacology. B-Lymphocytes / drug effects. CD40 Ligand / biosynthesis. Gene Expression Regulation, Leukemic / drug effects. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasm Proteins / biosynthesis. Phosphatidylinositol 3-Kinases / physiology. RNA Stability / drug effects. Signal Transduction / drug effects. Thalidomide / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Nov 1;96(9):2917-24 [11049967.001]
  • [Cites] Leukemia. 2010 Nov;24(11):1893-900 [20882050.001]
  • [Cites] Br J Haematol. 2001 Jul;114(1):107-10 [11472353.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2033-9 [11932906.001]
  • [Cites] Nat Med. 2003 Mar;9(3):279-86 [12579196.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):955-61 [14997189.001]
  • [Cites] J Immunol. 1979 Mar;122(3):1087-90 [376702.001]
  • [Cites] Blood. 1982 Nov;60(5):1075-81 [6215074.001]
  • [Cites] Am J Clin Pathol. 1987 Jan;87(1):60-5 [2948384.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):279-83 [2446736.001]
  • [Cites] Clin Exp Immunol. 1988 Jul;73(1):160-2 [3168330.001]
  • [Cites] Blood. 1989 Feb;73(2):366-8 [2492832.001]
  • [Cites] Anal Biochem. 1995 Jan 1;224(1):382-9 [7710096.001]
  • [Cites] J Immunol. 1995 May 15;154(10):4996-5010 [7537298.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1902-9 [7475282.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Nat Med. 1997 Sep;3(9):984-9 [9288724.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4940-7 [9354461.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2689-97 [9531577.001]
  • [Cites] J Immunol. 1999 Apr 1;162(7):4037-44 [10201926.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):82-5 [10485710.001]
  • [Cites] Biotechniques. 2004 Dec;37(6):961-9 [15597545.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3193-8 [15339846.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1797-805 [15965501.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5984-92 [16115943.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3940-7 [16099873.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11712-20 [16357183.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):480-8 [16750498.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3450-7 [16741250.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):47-52 [17532765.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11 [17576924.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Oct;293(4):G719-28 [17640979.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:332-8 [18024648.001]
  • [Cites] Vaccine. 2007 Dec 21;26(1):82-7 [18053620.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):396-404 [18223214.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52 [18287027.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2519-25 [18427150.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4650-7 [18628480.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Sep;21(3):421-36 [18790447.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5180-9 [18772452.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):53-8 [19147079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9 [19470455.001]
  • [Cites] RNA Biol. 2009 Jul-Aug;6(3):259-65 [19395873.001]
  • [Cites] Int J Cancer. 2009 Dec 15;125(12):2863-70 [19609947.001]
  • [CommentIn] Blood. 2010 Apr 1;115(13):2563-4 [20360474.001]
  • (PMID = 19965642.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00466895
  • [Grant] United States / NCI NIH HHS / CA / P01 CA95426; United States / NCI NIH HHS / CA / P50 CA140158; United States / NCI NIH HHS / CA / 1K12 CA133250; United States / NCI NIH HHS / CA / P01 CA101956; United States / NCI NIH HHS / CA / P50-CA140158; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / K12 CA133250
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / DNA-Binding Proteins; 0 / NFATC Transcription Factors; 0 / NFATC1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / Tumor Protein p73; 0 / Tumor Suppressor Proteins; 0 / p73 protein, human; 147205-72-9 / CD40 Ligand; 4Z8R6ORS6L / Thalidomide; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ PMC2852364
  •  go-up   go-down


46. Chae HW, Kim IW, Jin HE, Kim DD, Chung SJ, Shim CK: Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine. Arch Pharm Res; 2008 Jan;31(1):103-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to examine the effect of ion-pair complexation with endogenous bile salts on the transport of a quarternary ammonium organic cationic (OC) drug, berberine, across the Caco-2 and LLC-PK1 cell monolayers.
  • Similar results were observed for the transport of berberine across the LLC-PK1 cells.
  • These results suggest that an efflux transporter, probably P-gp, is involved in the Caco-2 cell transport.
  • The apparent partition coefficient (APC) of berberine between n-octanol and a phosphate buffer (pH 7.4) was increased by the presence of an organic anion (OA), taurodeoxycholate (TDC, a bile salt), suggesting the formation of a lipophilic ion-pair complex between an OC (berberine) and an OA (TDC).
  • Despite the ion-pair complexation, however, the BL-AP transport of berberine across the Caco-2 and LLC-PK1 cells was not altered by the cis-presence of bile salts or the rat bile juice.
  • This is consistent with the reportedly unaltered secretory transport of a quarternary ammonium compound, tributylmethylammonium (TBuMA), across the Caco-2 cell monolayers in the cis-presence of bile salts or the rat bile juice, but not with our previous report in which the secretory transport of TBuMA across the LLC-PK1 cell was increased in the cis-presence of TDC.
  • Therefore, the effect of ion-pair formation with the bile components or bile salts on the secretory transport of OCs appears to depend on the molecular properties of OCs (e.g., molecular weight, lipophilicity and affinity to relevant transporters) and the characteristics of cell strains (e.g., expression and contribution of responsible transporters to the transport).
  • [MeSH-minor] Animals. Biological Transport, Active. Caco-2 Cells. Cell Membrane / metabolism. Chemistry, Physical. Chromatography, High Pressure Liquid. Data Interpretation, Statistical. Humans. LLC-PK1 Cells. P-Glycoprotein / antagonists & inhibitors. P-Glycoprotein / metabolism. Physicochemical Phenomena. Solubility. Swine. Taurodeoxycholic Acid / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277615.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / P-Glycoprotein; 0I8Y3P32UF / Berberine; 516-50-7 / Taurodeoxycholic Acid
  •  go-up   go-down


47. Moore DA, Fuller B, Hazzan M, Jones JW: Development of a security vulnerability assessment process for the RAMCAP chemical sector. J Hazard Mater; 2007 Apr 11;142(3):689-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a security vulnerability assessment process for the RAMCAP chemical sector.
  • The Department of Homeland Security (DHS), Directorate of Information Analysis & Infrastructure Protection (IAIP), Protective Services Division (PSD), contracted the American Society of Mechanical Engineers Innovative Technologies Institute, LLC (ASME ITI, LLC) to develop guidance on Risk Analysis and Management for Critical Asset Protection (RAMCAP).
  • AcuTech Consulting Group (AcuTech) has been contracted by ASME ITI, LLC, to provide assistance by facilitating the development of sector-specific guidance on vulnerability analysis and management for critical asset protection for the chemical manufacturing, petroleum refining, and liquefied natural gas (LNG) sectors.
  • This activity involves two key tasks for these three sectors: Development of a screening to supplement DHS understanding of the assets that are important to protect against terrorist attack and to prioritize the activities.
  • Development of a standard security vulnerability analysis (SVA) framework for the analysis of consequences, vulnerabilities, and threats.
  • This project involves the cooperative effort of numerous leading industrial companies, industry trade associations, professional societies, and security and safety consultants representative of those sectors.
  • Jones is the chief technology officer for ASME-ITI, LLC for RAMCAP.

  • MedlinePlus Health Information. consumer health - Disaster Preparation and Recovery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920260.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Hazardous Substances
  •  go-up   go-down


48. Nikitin EA, Malakho SG, Biderman BV, Baranova AV, Lorie YY, Shevelev AY, Peklo MM, Vlasik TN, Moskalev EA, Zingerman BV, Vorob'ev IA, Poltaraus AB, Sudarikov AB, Vorobjev AI: Expression level of lipoprotein lipase and dystrophin genes predict survival in B-cell chronic lymphocytic leukemia. Leuk Lymphoma; 2007 May;48(5):912-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression level of lipoprotein lipase and dystrophin genes predict survival in B-cell chronic lymphocytic leukemia.
  • Mutational status of immunoglobulin variable region genes (VH-genes) is known as the strongest predictor of long term prognosis in B-CLL.
  • In this study, we have compared prognostic values of real time PCR quantification of the expression levels of four genes previously shown to be differentially expressed in V(H)-unmutated and mutated B-CLL subtypes: ZAP-70, ZBTB20, DMD and LPL.
  • The study included 134 B-CLL patients.
  • Prognostic values of LPL gene expression levels were significant even for CLL patients with stage A.
  • [MeSH-major] Dystrophin / biosynthesis. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lipoprotein Lipase / biosynthesis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487735.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R15CA113331-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dystrophin; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


49. Oumeish OY, Oumeish I, Tarawneh M, Salman T, Sharaiha A: Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol; 2006 Mar;45(3):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature.
  • These findings were suggestive of lymphoma.
  • They revealed total replacement of the nodular architecture by a diffuse proliferation of mature lymphoid cells having small nuclei and a crumbled chromatin pattern, and very rare mitosis.
  • It was concluded from the lymph node biopsies that these changes were typical of non-Hodgkin's lymphoma, diffuse and small cell type, of low-grade malignancy.
  • A bone marrow aspirate showed a marrow heavily infiltrated by lymphoid cells with some immaturity.
  • The bone marrow picture was consistent with diffuse, well-differentiated non-Hodgkin's lymphoma, developing into chronic lymphocytic leukemia (CLL).
  • Endoscopy showed antral-type gastric mucosa exhibiting mild chronic gastritis.
  • Skin biopsy from a fresh lesion on the back showed a diffuse inflammatory cell infiltrate with collections of histiocytic cells.
  • The blood picture also showed monoclonal IgG paraprotein (3170 mg/dL) of the kappa light chain type.
  • The patient was treated by the oncologist for her lymphoma, and was given Cytoxan, prednisolone, endoxan, Leukeran, and melphalan.
  • [MeSH-major] Granuloma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / complications. Necrobiotic Disorders / pathology. Paraproteinemias / etiology. Xanthomatosis / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Xanthogranuloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533236.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
  •  go-up   go-down


50. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, Laoutaris N, Karlsson K, Baran-Marzsak F, Tsaftaris A, Moreno C, Anagnostopoulos A, Caligaris-Cappio F, Vaur D, Ouzounis C, Belessi C, Ghia P, Davi F, Rosenquist R, Stamatopoulos K: Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood; 2008 Feb 1;111(3):1524-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.
  • Somatic hypermutation (SHM) features in a series of 1967 immunoglobulin heavy chain gene (IGH) rearrangements obtained from patients with chronic lymphocytic leukemia (CLL) were examined and compared with IGH sequences from non-CLL B cells available in public databases.
  • SHM analysis was performed for all 1290 CLL sequences in this cohort with less than 100% identity to germ line.
  • At the cohort level, SHM patterns were typical of a canonical SHM process.
  • However, important differences emerged from the analysis of certain subgroups of CLL sequences defined by:.
  • Recurrent, "stereotyped" amino acid changes occurred across the entire IGHV region in CLL subsets carrying stereotyped HCDR3 sequences, especially those expressing the IGHV3-21 and IGHV4-34 genes.
  • These mutations are underrepresented among non-CLL sequences and thus can be considered as CLL-biased.
  • Furthermore, it was shown that even a low level of mutations may be functionally relevant, given that stereotyped amino acid changes can be found in subsets of minimally mutated cases.
  • The precise targeting and distinctive features of somatic hypermutation (SHM) in selected subgroups of CLL patients provide further evidence for selection by specific antigenic element(s).
  • [MeSH-major] Antigens, Neoplasm / immunology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Somatic Hypermutation, Immunoglobulin / genetics. Somatic Hypermutation, Immunoglobulin / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17959859.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Antigens, Neoplasm
  •  go-up   go-down


51. Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, Keating MJ: Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol; 2008 Apr;141(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
  • CD20 is an important therapeutic target in chronic lymphocytic leukaemia (CLL).
  • The median numbers of CD20 antigen sites by FISH subtypes were: 17p- (n = 26), 9341 per cell; 11q- (n = 42), 5886 per cell; +12 (n = 93), 23 603 per cell; negative FISH (n = 153), 8828 per cell; and 13q- (n = 196), 10 781 per cell.
  • Compared to cases with negative FISH, 11q- cases had significantly lower CD20 expression (P = 0.001), and +12 cases had significantly higher CD20 expression (P < 0.001).
  • The significance of trisomy 12 and high CD20 expression was maintained after multivariate analysis accounting for other disease characteristics.
  • Fifty-nine patients received the combination of rituximab and granulocyte-macrophage colony-stimulating factor as frontline therapy; responses were observed in 13 of 14 (93%) patients with +12, in two of four (50%) patients with 11q-, and in 30 of 41 (73%) patients with negative FISH, 13q- or 17p- CLL.
  • Patients with trisomy 12 CLL showed strong leukemic cell CD20 expression and had a high rate of response to rituximab-based therapy.
  • [MeSH-major] Antigens, CD20 / blood. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / immunology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324964.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


52. Mueller-Garamvölgyi E, Perren A, Schmitt A: [Pathology of malignant lymphomas--clarity instead of confusion]. Ther Umsch; 2010 Oct;67(10):497-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathology of malignant lymphomas--clarity instead of confusion].
  • [Transliterated title] Pathologie maligner Lymphome--Klarheit statt Wirrwarr.
  • After decades of confusion in lymphoma classification clearness was achieved with the publication of the REAL classification 1994 and of the WHO classification 2001.
  • The WHO classification comprises B- and T-lymphoblastic neoplasms, mature B-cell lymphomas, mature T-cell and NK-cell lymphomas and Hodgkin lymphomas.
  • A modern diagnostic work-up of lymphomas is based on morphology, immunohistochemistry and increasingly on molecular studies.
  • The aim is to give an overview of the most frequent mature B-cell lymphomas and the most important classical Hodgkin lymphomas with focus on morphology and immunohistochemistry.
  • [MeSH-major] Lymphoma / pathology
  • [MeSH-minor] Disease Progression. Hodgkin Disease / classification. Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / classification. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymph Nodes / pathology. Lymphoma, Follicular / classification. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse. Prognosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886454.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


53. Han W, Liu KY, Xu LP, Chen H, Liu DH, Chen YH, Zhang XH, Zhang YC, Chen Y, Wang Y, Wang J, Lu DP, Huang XJ: [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib]. Zhonghua Yi Xue Za Zhi; 2008 Jul 22;88(28):1974-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib].
  • OBJECTIVE: To investigate the effect of allogeneic hemopoietic stem cell transplantation (HSCT) in patients with acute lymphocytic leukemia (ALL) or chronic myelocytic leukemia (CML) resistant to imatinib mesylate (IM).
  • Eight cases received recombinant human granulocyte-colony stimulating factor (rhG-CSF) mobilized bone marrow transplantation plus peripheral blood stem cell transplantation (PBSCT), and 6 only received PBSCT.
  • Nine of the 14 patients developed acute graft versus host disease (GVHD), 7 being in the grade II and 2 being in grade III; and 6 of the 13 evaluable patients developed extensive chronic GVHD.
  • CONCLUSION: Allo-HSCT can be an important salvage option for patients with Ph (+) chromosome with leukemia resistant to IM.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062738.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


54. Quintás-Cardama A, Yeh RK, Hollyman D, Stefanski J, Taylor C, Nikhamin Y, Imperato G, Sadelain M, Rivière I, Brentjens RJ: Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther; 2007 Dec;18(12):1253-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.
  • However, low transduction efficiencies may hamper the efficacy of such therapeutic strategies in the clinical setting.
  • Here we present data investigating the impact of temperature, speed, and frequency of spinoculation on T cell transduction efficiencies.
  • Under these conditions, enhanced gene transfer was observed in T cells derived from healthy donors, using research-grade vector stocks.
  • Significantly, application of these enhanced transduction conditions to T cells derived from previously treated patients with chronic lymphocytic leukemia allowed for adequate gene transfer under both small-scale and large-scale clinically applicable conditions using either preclinical or current Good Manufacturing Practice-grade gammaretroviral vector stocks.
  • [MeSH-major] Genetic Therapy. Genetic Vectors / genetics. Retroviridae / genetics. T-Lymphocytes. Transduction, Genetic / methods

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Gene Ther. 2008 Jun;19(6):655-6; author reply 657-8 [18578630.001]
  • (PMID = 18052719.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA95152; United States / NCI NIH HHS / CA / P01 CA086438; United States / NCI NIH HHS / CA / P30 CA-088748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Fernández-Calotti P, Gamberale R, Costas M, Sánchez Avalos J, Geffner J, Giordano M: Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway. Int Immunopharmacol; 2006 May;6(5):715-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fludarabine is a nucleoside analogue that has been successfully employed for the treatment of low-grade lymphoid malignancies and, more recently, in nonmyeloablative preparative regimens for stem cell transplantation, due to its strong cytotoxic activity on lymphocytes.
  • Finally, we showed that fludarabine induced the activation of the transcription factor AP-1 not only in monocytic cells but also in non-proliferating lymphocytes from chronic lymphocytic leukemia.
  • It is possible that some of fludarabine side effects in vivo may be attributed to cell activation/differentiation rather than induction of apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. B-Lymphocytes / drug effects. Monocytes / drug effects. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546701.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Interleukin-8; 0 / Transcription Factor AP-1; 126547-89-5 / Intercellular Adhesion Molecule-1; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


56. Eid M, Kayed H, El-Bassyouni HT: Polyploidy in chronic lymphocytic leukemia with p53 deletion detected by fish: a case report. Cases J; 2009 Sep 11;2:8872
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyploidy in chronic lymphocytic leukemia with p53 deletion detected by fish: a case report.
  • We report a case of chronic lymphocytic leukemia with a characteristic cytogenetics finding detected by fluorescent in situ hybridization.
  • To our knowledge polyploidy is not commonly reported with chronic lymphocytic leukemia patients.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] Leukemia. 2009 Jan;23(1):117-24 [18843282.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700 [15865924.001]
  • [Cites] Leuk Res. 2008 Jul;32(7):1071-7 [18035414.001]
  • [Cites] Trends Cell Biol. 2008 May;18(5):244-52 [18406616.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 1;158(1):88-91 [15771912.001]
  • (PMID = 20184701.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827117
  •  go-up   go-down


57. Gibbs SD, Westerman DA, Lade S, McCormack C, Seymour JF, Prince HM: Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count. J Am Acad Dermatol; 2005 Sep;53(3):535-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Skin Diseases / etiology


58. Additional abstracts from the XII International Workshop on Chronic Lymphocytic Leukemia. September 14-16, 2007. London, United Kingdom. Leuk Lymphoma; 2007 Nov;48(11):2267-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional abstracts from the XII International Workshop on Chronic Lymphocytic Leukemia. September 14-16, 2007. London, United Kingdom.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398965.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] England
  •  go-up   go-down


59. Schwarzmeier JD, Hubmann R, Düchler M, Jäger U, Shehata M: Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia. Leuk Lymphoma; 2005 Feb;46(2):157-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia.
  • The original observation that sera from patients with chronic B-cell lymphocytic leukemia (B-CLL) contain high amounts of soluble CD23 (sCD23), which reflect disease activity and tumor load has been confirmed by numerous reports and serial determinations of sCD23 are now recognized as important indicators of disease progression.
  • Following is an update on clinical data and a short review on the potential functions of CD23 as well as its regulation by Notch2 in B-CLL.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Receptors, Cell Surface / physiology. Receptors, IgE / genetics
  • [MeSH-minor] Cell Lineage. Gene Expression Regulation. Humans. Receptor, Notch2

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621797.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NOTCH2 protein, human; 0 / Receptor, Notch2; 0 / Receptors, Cell Surface; 0 / Receptors, IgE
  • [Number-of-references] 80
  •  go-up   go-down


60. Li HX, Yan FH, Lei L: [Effects of Porphyromonas gingivalis lipopolysaccharide on apoptotic genes in foam cells]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 May;45(5):274-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Macrophages from THP-1 monocytes and foam cells from macrophages by oxLDL inducement were treated with oxidized low density lipoprotein (oxLDL) or oxLDL+ Pg-LPS.
  • Cell apoptosis was detected by acridine orange-ethidium bromide (AO-EB) staining.
  • RESULTS: Pg-LPS enhanced cell apoptosis rate during and after foam cells formation [(5.47+/-0.93)% vs. (7.50+/-0.54)%].
  • PCR array demonstrated that it increased B-cell CLL-lymphoma 2 (BCL2) related protein A1 (BCL2A1) transcription during foam cells formation (>2 fold), and promoted BCL2 and BCL2A1 transcription after foam cells formation (>2 fold).
  • CONCLUSIONS: Pg-LPS affected apoptotic gene transcription during and after foam cells formation and enhanced cell apoptosis.
  • [MeSH-minor] Caspase 3 / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Gene Expression. Humans. Lipoproteins, LDL / pharmacology. Macrophages / physiology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654241.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL2-related protein A1; 0 / Lipopolysaccharides; 0 / Lipoproteins, LDL; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; 0 / oxidized low density lipoprotein; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


61. Scielzo C, Ghia P, Conti A, Bachi A, Guida G, Geuna M, Alessio M, Caligaris-Cappio F: HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest; 2005 Jun;115(6):1644-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.
  • We used a proteomic approach for identifying molecules involved in the pathogenesis of chronic lymphocytic leukemia (CLL).
  • The 2 patient subsets differed in the expression of hematopoietic lineage cell-specific protein 1 (HS1).
  • This difference was investigated in a larger cohort of 26 unselected patients.
  • As HS1 is a protein pivotal in the signal cascade triggered by B cell receptor (BCR) stimulation, we studied its pattern of expression following BCR engagement.
  • These data indicate a central role for antigen stimulation in CLL and suggest a new therapeutic target for patients with aggressive disease.
  • [MeSH-major] B-Lymphocytes / metabolism. Biomarkers, Tumor / biosynthesis. Blood Proteins / biosynthesis. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • [MeSH-minor] ADP-ribosyl Cyclase / biosynthesis. Aged. Aged, 80 and over. Antigens, CD / biosynthesis. Antigens, CD38. Case-Control Studies. Female. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Heavy Chains / metabolism. Immunoglobulin M / biosynthesis. Immunoglobulin M / genetics. Immunoglobulin Variable Region / genetics. Immunoglobulin Variable Region / metabolism. Male. Membrane Glycoproteins. Middle Aged. Phosphorylation. Prognosis. Protein Processing, Post-Translational / genetics. Receptors, Antigen, B-Cell / biosynthesis. Receptors, Antigen, B-Cell / genetics. Somatic Hypermutation, Immunoglobulin / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2036-41 [15514014.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1365-74 [8695855.001]
  • [Cites] J Exp Med. 1997 Apr 7;185(7):1387-92 [9104825.001]
  • [Cites] Blood. 1998 Jan 1;91(1):244-51 [9414291.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4506-12 [9794375.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):7557-64 [10066823.001]
  • [Cites] Immunity. 1999 Feb;10(2):239-48 [10072076.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1199-206 [10666191.001]
  • [Cites] Adv Cancer Res. 2000;79:157-73 [10818680.001]
  • [Cites] Anal Chem. 2000 Jun 1;72(11):2482-9 [10857624.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2262-4 [11877310.001]
  • [Cites] Proteomics. 2001 Nov;1(11):1359-63 [11922595.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4087-93 [12010811.001]
  • [Cites] Proteomics. 2002 Sep;2(9):1267-76 [12362345.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4609-14 [12393534.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1087-93 [12393552.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1262-9 [12406914.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4952-7 [12586612.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2146-55 [12763926.001]
  • [Cites] J Neurotrauma. 2004 Jul;21(7):854-63 [15307898.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):519-25 [15314077.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2499-504 [15217828.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2879-85 [15217826.001]
  • [Cites] Cancer. 1977 Aug;40(2):855-64 [890666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5913-7 [2503826.001]
  • [Cites] Hematol Oncol Clin North Am. 1990 Apr;4(2):447-56 [2182601.001]
  • [Cites] Cell. 1992 Nov 13;71(4):649-62 [1423621.001]
  • [Cites] Curr Opin Immunol. 1992 Dec;4(6):703-10 [1281638.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3631-5 [7682714.001]
  • [Cites] Immunol Today. 1994 Jun;15(6):288-94 [7520700.001]
  • [Cites] Immunol Lett. 1994 Apr;40(1):65-71 [7927516.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3664-78 [7641686.001]
  • [Cites] Biochemistry. 1996 Apr 23;35(16):5327-32 [8611520.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2615-20 [8639876.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1678-85 [15466924.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • (PMID = 15931393.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / HCLS1 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin M; 0 / Immunoglobulin Variable Region; 0 / Membrane Glycoproteins; 0 / Receptors, Antigen, B-Cell; EC 3.2.2.5 / ADP-ribosyl Cyclase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  • [Other-IDs] NLM/ PMC1136999
  •  go-up   go-down


62. Montes-Ares O, Moya-Quiles MR, Montes-Casado M, Guerra-Pérez N, Campillo JA, González C, López-Bermejo A, Tamayo M, Majado MJ, Parrado A, Muro M, Marín L, Alvarez-López MR: Human leucocyte antigen-C in B chronic lymphocytic leukaemia. Br J Haematol; 2006 Nov;135(4):517-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human leucocyte antigen-C in B chronic lymphocytic leukaemia.
  • This study aimed at characterising the distribution of human leucocyte antigen (HLA)-C alleles in a large group of patients with B chronic lymphocytic leukaemia from Southeastern Spain.
  • [MeSH-major] HLA-C Antigens / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Histocompatibility Testing / methods. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054674.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA-C Antigens
  •  go-up   go-down


63. Hartman WR, Pelleymounter LL, Moon I, Kalari K, Liu M, Wu TY, Escande C, Nin V, Chini EN, Weinshilboum RM: CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system. Leuk Lymphoma; 2010 Jul;51(7):1315-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system.
  • Its expression is a prognostic marker for chronic lymphocytic leukemia.
  • We have characterized individual variation in CD38 expression in lymphoblastoid cell lines from 288 healthy subjects of three ethnicities.
  • The CD38 gene was then resequenced using DNA from the same cell lines, with the identification of 53 single nucleotide polymorphisms (SNPs) and one indel, 39 novel.
  • We also determined that variation in CD38 expression in these cell lines was associated with variation in antineoplastic drug sensitivity.

  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859327 for PMID:20470215 [PharmGKB] .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Mar;24(3):236-44 [10700175.001]
  • [Cites] Biol Cell. 2000 Jul;92(3-4):197-204 [11043408.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):422-5 [12567189.001]
  • [Cites] Bioessays. 2003 Jul;25(7):683-90 [12815723.001]
  • [Cites] Leukemia. 2004 Jan;18(1):180-2 [14523466.001]
  • [Cites] Novartis Found Symp. 2004;259:197-205; discussion 205-7, 223-5 [15171255.001]
  • [Cites] Nature. 2004 Aug 12;430(7001):743-7 [15269782.001]
  • [Cites] Biochem J. 2004 Sep 15;382(Pt 3):e5-6 [15352307.001]
  • [Cites] Genetics. 1989 Nov;123(3):585-95 [2513255.001]
  • [Cites] J Biol Chem. 1995 Dec 22;270(51):30327-33 [8530456.001]
  • [Cites] Am J Physiol. 1996 Oct;271(4 Pt 1):C1007-24 [8897805.001]
  • [Cites] Immunity. 1997 Sep;7(3):315-24 [9324352.001]
  • [Cites] Diabetologia. 1998 Sep;41(9):1024-8 [9754820.001]
  • [Cites] Immunogenetics. 1999 Jul;49(7-8):597-604 [10369916.001]
  • [Cites] Biol Chem. 1999 Jul-Aug;380(7-8):785-93 [10494827.001]
  • [Cites] J Comput Biol. 2005 Jul-Aug;12(6):882-93 [16108723.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1365-9 [16251966.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):43121-30 [16207712.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jul 14;345(4):1386-92 [16730329.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C227-39 [16790499.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4791-801 [18559526.001]
  • [Cites] Physiol Rev. 2008 Jul;88(3):841-86 [18626062.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5997-6005 [18632656.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7050-8 [18757419.001]
  • [Cites] Nat Rev Genet. 2009 Sep;10(9):595-604 [19636342.001]
  • [Cites] Cancer Cell. 2009 Sep 8;16(3):259-66 [19732725.001]
  • [Cites] Leuk Res. 2001 Nov;25(11):927-32 [11597727.001]
  • (PMID = 20470215.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA132780-02; United States / NIGMS NIH HHS / GM / T32 GM08685; United States / NIGMS NIH HHS / GM / U01 GM61388; United States / NCI NIH HHS / CA / R01 CA132780-02; United States / NIGMS NIH HHS / GM / R01 GM028157; United States / NIGMS NIH HHS / GM / U01 GM061388; United States / NCI NIH HHS / CA / R01 CA132780; United States / NIGMS NIH HHS / GM / R01 GM28157; United States / NIDDK NIH HHS / DK / R01 DK084055; United States / NIGMS NIH HHS / GM / GM061388-10; United States / NIGMS NIH HHS / GM / T32 GM008685; United States / NIGMS NIH HHS / GM / U01 GM061388-10; United States / NIGMS NIH HHS / GM / GM028157-29; United States / NIGMS NIH HHS / GM / R01 GM028157-29; United States / NIGMS NIH HHS / GM / T32 GM008685-12; United States / NIGMS NIH HHS / GM / GM008685-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers; 0 / RNA, Messenger; 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ NIHMS198605; NLM/ PMC2892000
  •  go-up   go-down


64. Caldas LA, Attias M, de Souza W: Dynamin inhibitor impairs Toxoplasma gondii invasion. FEMS Microbiol Lett; 2009 Nov;301(1):103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that previous incubation of the host cells, but not the parasites, with Dynasore, a small molecule that inhibits dynamin GTPase activity, markedly reduced the penetration of T. gondii tachyzoites into LLC-MK2 cells.
  • In contrast, parasite adhesion to the host cell surface increased, as observed both by light and electron microscopy.
  • Intriguingly, the few parasites internalized by Dynasore-treated cells remained in vacuoles located at the periphery of the cell, in contrast to the perinuclear localization seen in the control.
  • [MeSH-minor] Animals. Cell Adhesion. Cell Line. Dose-Response Relationship, Drug. Host-Parasite Interactions. Humans. Hydrazones / administration & dosage. Macaca mulatta. Mice. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Vacuoles / metabolism. Vacuoles / parasitology

  • MedlinePlus Health Information. consumer health - Toxoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817867.001).
  • [ISSN] 1574-6968
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazones; 0 / N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide; EC 3.6.5.5 / Dynamins
  •  go-up   go-down


65. Majumder D, Banerjee D, Chandra S, Banerjee S, Chakrabarti A: Red cell morphology in leukemia, hypoplastic anemia and myelodysplastic syndrome. Pathophysiology; 2006 Dec;13(4):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red cell morphology in leukemia, hypoplastic anemia and myelodysplastic syndrome.
  • In the present work, we have studied the overall morphology of intact red cells in different leukemic patients along with patients of hypoplastic anemia (HPA) by scanning electron microscopy.
  • We have also studied the ultrastructure of the red cell surface membranes by transmission electron microscopy.
  • We have shown direct evidence of the altered red cell (RBC) membrane morphology irrespective of the hemoglobin status of the patients which includes (1) presence of large central holes in RBCs of acute myeloid leukemia (AML), (2) presence of thorn- and horn-like structure in RBCs of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) and (3) flaccid appearance of RBCs in chronic lymphocytic leukemia (CLL) patients.
  • TEM studies revealed presence of pores with diameters ranging from 100 to 200nm on the RBC membrane surface of myeloid leukemia with AML being the most prominent among others.
  • Such pathophysiological alterations of the RBC morphology in leukemic patients could be identified as characteristic signature of the onset of anemia associated with the disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876391.001).
  • [ISSN] 0928-4680
  • [Journal-full-title] Pathophysiology : the official journal of the International Society for Pathophysiology
  • [ISO-abbreviation] Pathophysiology
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Ghiotto F, Fais F, Albesiano E, Sison C, Valetto A, Gaidano G, Reinhardt J, Kolitz JE, Rai K, Allen SL, Ferrarini M, Chiorazzi N: Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. Mol Med; 2006 Nov-Dec;12(11-12):300-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia.
  • Analyses of Ig V(H)DJ(H) rearrangements expressed by B-CLL cells have provided insights into the antigen receptor repertoire of B-CLL cells and the maturation stages of B-lymphocytes that give rise to this disease.
  • However, less information is available about the L chain V gene segments utilized by B-CLL cells and to what extent their characteristics resemble those of the H chain.
  • We analyzed the V(L) and J(L) gene segments of 206 B-CLL patients, paying particular attention to frequency of use and association, mutation status, and LCDR3 characteristics.
  • Approximately 40% of B-CLL cases express V(L) genes that differ significantly from their germline counterparts.
  • These findings are reminiscent of the expressed VH repertoire in B-CLL.
  • However unlike the V(H) repertoire, V(L) gene use was not significantly different than that of normal B-lymphocytes.
  • These similarities and differences between the IgH and IgL V gene repertoires expressed in B-CLL suggest some novel features while also reinforcing concepts derived from studies of the IgH repertoire.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Jun 5;191(11):1813-7 [10839798.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2137-45 [9973488.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):95-102 [11123281.001]
  • [Cites] J Immunol Methods. 2001 Jul 1;253(1-2):23-36 [11384666.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):968-76 [8993018.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1614-27 [9120005.001]
  • [Cites] J Mol Biol. 1997 Apr 25;268(1):69-77 [9149142.001]
  • [Cites] J Clin Invest. 1997 Oct 1;100(7):1667-76 [9312164.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1073-83 [9323135.001]
  • [Cites] J Mol Biol. 1998 Jan 16;275(2):269-94 [9466909.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):688-94 [9710436.001]
  • [Cites] Mol Med. 1998 Aug;4(8):525-53 [9742508.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3075 [14527893.001]
  • [Cites] Mol Immunol. 2004 Jan;40(10):647-60 [14644091.001]
  • [Cites] Genes Dev. 2004 Jan 1;18(1):1-11 [14724175.001]
  • [Cites] J Clin Invest. 2004 Apr;113(7):1008-16 [15057307.001]
  • [Cites] Blood. 2004 May 1;103(9):3490-5 [14695232.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4389-95 [14962897.001]
  • [Cites] J Exp Med. 2004 Jul 19;200(2):191-9 [15263026.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):519-25 [15314077.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2499-504 [15217828.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2879-85 [15217826.001]
  • [Cites] Nature. 1979 Oct 18;281(5732):605-6 [492328.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):727-33 [6092962.001]
  • [Cites] Immunol Today. 1994 Aug;15(8):367-73 [7916950.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4952-7 [12586612.001]
  • [Cites] Annu Rev Immunol. 2003;21:841-94 [12615894.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4087-93 [12010811.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2262-4 [11877310.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):383-9 [11828014.001]
  • [Cites] J Exp Med. 1999 Sep 6;190(5):691-704 [10477553.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1636-43 [15902303.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3575-83 [16076869.001]
  • [Cites] Ann N Y Acad Sci. 2005 Dec;1062:1-12 [16461783.001]
  • [Cites] Immunity. 2000 Jul;13(1):37-45 [10933393.001]
  • [Cites] Immunol Today. 1994 Jun;15(6):288-94 [7520700.001]
  • [Cites] Immunol Today. 1994 Jan;15(1):27-32 [8136008.001]
  • [Cites] J Immunol. 1993 Oct 1;151(7):3604-16 [8376796.001]
  • [Cites] Science. 1987 Nov 6;238(4828):791-3 [3118465.001]
  • [Cites] Nature. 1987 Aug 27-Sep 2;328(6133):805-11 [3498121.001]
  • [Cites] Science. 1985 Mar 29;227(4694):1597-601 [3975629.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1507-17 [7535340.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3902-11 [7706729.001]
  • [Cites] Semin Immunol. 1994 Dec;6(6):347-60 [7654992.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):235-46 [8977195.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • (PMID = 17380195.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087956; United States / NCI NIH HHS / CA / R01 CA81554; United States / NCRR NIH HHS / RR / M01 RR018535; United States / NCI NIH HHS / CA / R01 CA081554; United States / NCI NIH HHS / CA / R01 CA87956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA, Complementary; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Joining Region; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin M; 0 / Immunoglobulin Variable Region; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1829199
  •  go-up   go-down


67. Kampfenkel T, Baraniskin A, Teschendorf C, Schmiegel W, Massenkeil G: A rare case of chronic lymphocytic leukemia with hypercalcemia induced by elevated parathyroid hormone-related peptides. Acta Haematol; 2010;124(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of chronic lymphocytic leukemia with hypercalcemia induced by elevated parathyroid hormone-related peptides.
  • Calcium elevation is induced by direct bone infiltration of a tumor mass or through calcium liberation from the skeleton by a humoral mediator.
  • The latter mechanism is referred to as humoral hypercalcemia of malignancy (HHM).
  • We report a patient with chronic lymphocytic leukemia and hypercalcemia induced by PTHrP.
  • In contrast to solid tumors and myeloma, PTHrP-induced HHM is very rare in low-grad lymphoma including chronic lymphocytic leukemia.
  • [MeSH-major] Hypercalcemia / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Parathyroid Hormone-Related Protein / blood

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20616540.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


68. Guggisberg K, Jordan RC: Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan;109(1):98-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature.
  • OBJECTIVE: Mantle cell lymphoma (MCL) is a rare B-cell neoplasm that has only recently been defined as a distinct entity.
  • Because of its rarity and histologic similarities to other small cell lymphomas, the microscopic diagnosis of MCL may be challenging.
  • This is particularly true within the oral cavity, where other lymphomas are more frequent.
  • Historical cases were reviewed, and available data regarding morphology, special stains, demographics, clinical presentation, radiographic findings, management, and outcome were extracted.
  • CONCLUSION: We conclude that MCL of the oral cavity is an uncommon diagnosis.
  • The microscopic diagnosis can be challenging, given its similar appearance to other small cell lymphomas, requiring a comprehensive immunohistochemical panel for the accurate diagnosis.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [Cites] Clin Oncol (R Coll Radiol). 2004 May;16(3):186-92 [15191005.001]
  • [Cites] J Oral Pathol. 1987 Jan;16(1):8-12 [3104566.001]
  • [Cites] Blood. 1990 Oct 1;76(7):1387-91 [2207314.001]
  • [Cites] Blood. 1991 Jul 15;78(2):259-63 [2070063.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):802-111 [8478674.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):249-56 [7612490.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):257-62 [7612491.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):627-40 [8619427.001]
  • [Cites] Curr Top Pathol. 1996;90:125-46 [8791750.001]
  • [Cites] Ear Nose Throat J. 1997 Jan;76(1):35-6 [9018933.001]
  • [Cites] J Oral Pathol Med. 1997 Jul;26(6):283-9 [9234189.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1785-91 [11681422.001]
  • [Cites] Ann Hematol. 2004 Feb;83(2):71-7 [14669040.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):316-20 [12973287.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Nov;92(5):519-25 [11709688.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):391-5 [16053848.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] J Laryngol Otol. 1998 Oct;112(10):991-4 [10211231.001]
  • [Cites] Head Neck. 1999 May;21(3):247-54 [10208668.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):29-38 [16173960.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):637-40 [1530105.001]
  • [Cites] Cancer. 2008 Aug 15;113(4):791-8 [18615506.001]
  • [Cites] Blood. 2008 Jan 15;111(2):558-65 [17962512.001]
  • [Cites] Histopathology. 2006 Mar;48(4):353-62 [16487357.001]
  • [Cites] Tumori. 2005 Nov-Dec;91(6):456-62 [16457141.001]
  • (PMID = 19880332.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / T32 DE017249; United States / NIDCR NIH HHS / DE / T32 DE017249-04; United States / NIDCR NIH HHS / DE / T32 DE017249-05; United States / NIDCR NIH HHS / DE / DE017249-04; United States / NIDCR NIH HHS / DE / T32 DE019096-02; United States / NIDCR NIH HHS / DE / DE017249-01; United States / NCI NIH HHS / CA / R21 CA095231; United States / NIDCR NIH HHS / DE / DE019096-02; United States / NIDCR NIH HHS / DE / T32 DE017249-03; United States / NCI NIH HHS / CA / R33 CA095231; United States / NIDCR NIH HHS / DE / T32 DE019096; United States / NIDCR NIH HHS / DE / T32DE017249; United States / NIDCR NIH HHS / DE / DE019096-01; United States / NIDCR NIH HHS / DE / T32 DE017249-02; United States / NIDCR NIH HHS / DE / DE017249-02; United States / NIDCR NIH HHS / DE / T32 DE019096-01; United States / NIDCR NIH HHS / DE / DE017249-03; United States / NIDCR NIH HHS / DE / T32 DE017249-01; United States / NIDCR NIH HHS / DE / DE017249-05; United States / NIDCR NIH HHS / DE / T32DE019096; United States / NCI NIH HHS / CA / CA095231
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  • [Number-of-references] 29
  • [Other-IDs] NLM/ NIHMS156688; NLM/ PMC2818374
  •  go-up   go-down


69. Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, Camp NJ, Spector LG, Leis JF, Morrison VA, Glenn M, Rabe KG, Achenbach SJ, Algood SD, Abbasi F, Fontaine L, Yau M, Rassenti LZ, Kay NE, Call TG, Hanson CA, Weinberg JB, Marti GE, Caporaso NE: Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol; 2010 Oct;151(2):152-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families.
  • Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic haematological condition characterized by low absolute levels of B-cell clones with a surface immunophenotype similar to that of chronic lymphocytic leukaemia (CLL).
  • It has been reported to be higher among first-degree relatives from CLL families.
  • We report results of multi-parameter flow cytometry among 505 first-degree relatives with no personal history of lymphoproliferative disease from 140 families having at least two cases of CLL.
  • MBL clustered in certain families but clustering was independent of the number of known CLL cases in a family.
  • As is the case with CLL, males had a significantly higher risk for MBL than did females (P = 0·04).
  • MBL patients had significantly higher mean absolute lymphocyte counts (2·4 × 10(9) /l) and B-cell counts (0·53 × 10(9) /l) than those with a normal B-cell immuno-phenotype.
  • Our findings show that MBL occurs at a very high rate in high risk CLL families.
  • Both the age and gender distribution of MBL are parallel to CLL, implying a shared inherited risk.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2010. This article is a US Government work and is in the public domain in the USA.
  • [Cites] Br J Haematol. 2009 Nov;147(3):339-46 [19709083.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3959-63 [19620484.001]
  • [Cites] Leukemia. 2010 Mar;24(3):512-20 [20090778.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2289-90 [12239136.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2337-42 [14630808.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):325-32 [16042682.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1087-91 [17577771.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Sep;72(5):344-53 [17266153.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Mayo Clin Proc. 2008 Jul;83(7):776-85 [18613994.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):493-7 [19347733.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4188-96 [19015397.001]
  • [Cites] Haematologica. 2009 May;94(5):647-53 [19286886.001]
  • [Cites] Blood. 2009 Jul 2;114(1):26-32 [19029437.001]
  • [Cites] Blood. 2009 Jul 2;114(1):33-7 [19420353.001]
  • [Cites] Leukemia. 2010 Jan;24(1):133-40 [19946263.001]
  • (PMID = 20738309.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118444; United States / NCI NIH HHS / PC / N01-PC-35141; United States / NCI NIH HHS / CA / N01PC35141; United States / NIAID NIH HHS / AI / P30 AI051445; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R43 CA137941; United States / NCI NIH HHS / CA / CA137941; United States / NIAID NIH HHS / AI / AI-51445; United States / NCI NIH HHS / CA / CA116237; United States / NCI NIH HHS / CA / U01 CA118444; United States / NCI NIH HHS / CA / R01 CA116237
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS230867; NLM/ PMC2966536
  •  go-up   go-down


70. Wei J, Zhou S, Bachem MG, Debatin KM, Beltinger C: Infiltration of blood outgrowth endothelial cells into tumor spheroids: role of matrix metalloproteinases and irradiation. Anticancer Res; 2007 May-Jun;27(3B):1415-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Infiltration of BOECs into spheroids made of tumor cells and fibroblasts was determined in the presence of low-dose EDTA, a potent inhibitor of MMPs.
  • RESULTS: Infiltration of BOECs into spheroids was blocked by low-dose EDTA.
  • Irradiation enhanced secretion of MMP-2 and, less so, of MMP-9 by tumor-stromal cells and tumor cells, and increased the amount of MMP-2 and -9 in subcutaneous LLC tumors.
  • [MeSH-major] Blood Cells / physiology. Cell Movement. Endothelial Cells / physiology. Matrix Metalloproteinase 2 / physiology. Matrix Metalloproteinase 9 / physiology. Spheroids, Cellular / physiology

  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595756.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 9G34HU7RV0 / Edetic Acid; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


71. Manolov I, Machulla HJ, Momekov G: Synthesis, physicochemical characterization and preliminary pharmacological in vitro evaluation of two novel cytotoxic benzophenone-linked 3,3-dimethyltriazenes. Pharmazie; 2006 Jun;61(6):511-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of the novel benzophenone-linked triazenes and of ten other 1-phenyl-3,3-dimethyl triazene derivatives as well as of the referent alkylating drug melphalan was assessed using the MTT-dye reduction assay.
  • A panel of human tumor cell lines was used: the chronic lymphoid leukemia SKW-3, the acute promyelocyte leukemia HL-60 and its multi-drug-resistant subline HL-60/Dox.
  • DNA-fragmentation analysis indicated that after 24 h treatment the novel benzophenone-linked triazenes induced programmed cell death in HL-60 cells.
  • [MeSH-minor] Cell Line. Chemistry, Physical. DNA Fragmentation / drug effects. DNA, Neoplasm / biosynthesis. HL-60 Cells. Humans. Models, Molecular. Physicochemical Phenomena. Structure-Activity Relationship. Tetrazolium Salts. Thiazoles

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826969.001).
  • [ISSN] 0031-7144
  • [Journal-full-title] Die Pharmazie
  • [ISO-abbreviation] Pharmazie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzophenones; 0 / DNA, Neoplasm; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Triazenes; 298-93-1 / thiazolyl blue
  •  go-up   go-down


72. Rankin JS, Orozco RE, Rodgers TL, Alfery DD, Glower DD: "Adjustable" artificial chordal replacement for repair of mitral valve prolapse. Ann Thorac Surg; 2006 Apr;81(4):1526-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gore & Associates Inc, Flagstaff, AZ) artificial chordal replacement and Carpentier ring annuloplasty (Edwards Lifesciences LLC, Irvine, CA), without leaflet resection.
  • Only 1 of 52 patients (1.9%) experienced late failure, and this patient was re-repaired with artificial chords.
  • Thus, "adjustable" artificial chordal replacement facilitates uniform repair of mitral valve prolapse with a low late failure rate.

  • MedlinePlus Health Information. consumer health - Mitral Valve Prolapse.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564319.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


73. Hwang HS, Min YS, Lee SC, Sun MK, Lim HS: Change of lip-line cant after 1-jaw orthognathic surgery in patients with mandibular asymmetry. Am J Orthod Dentofacial Orthop; 2009 Oct;136(4):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The purpose of this study was to investigate the change of lip-line cant (LLC) after 1-jaw orthognathic surgery in mandibular asymmetry patients.
  • LLC was measured in the preoperative and postoperative frontal photographs, and its change was correlated with various craniofacial measurements obtained from preoperative and postoperative frontal cephalograms and maxillofacial 3-dimensional computed tomography images.
  • RESULTS: Although these subjects had 2.4 degrees of LLC on average before surgery, LLC improved to 0.5 degrees after surgery, and the change (1.9 degrees ) was statistically significant.
  • In the correlation analysis, preoperative LLC showed positive correlations with menton deviation and mandibular anterior occlusal plane cant.
  • In the correlation analysis of LLC change, it had positive correlations with preoperative LLC and mandibular anterior occlusal plane cant and preoperative and postoperative change of menton deviation.
  • CONCLUSIONS: These results suggest that LLC is present with chin deviation, even without significant maxillary canting, and can be improved considerably by 1-jaw surgery alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815160.001).
  • [ISSN] 1097-6752
  • [Journal-full-title] American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
  • [ISO-abbreviation] Am J Orthod Dentofacial Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Seiffert M, Stilgenbauer S, Döhner H, Lichter P: Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia; 2007 Sep;21(9):1977-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids.
  • Accumulation of neoplastic cells in B-cell chronic lymphocytic leukemia (B-CLL) is thought to be due to intrinsic defects in the apoptotic machinery of the leukemic cells or to an altered, survival-stimulating microenvironment in vivo.
  • Despite their long survival in vivo, B-CLL cells undergo rapid spontaneous apoptosis ex vivo.
  • To maintain survival in vitro, we established a coculture system using the human bone marrow-derived stromal cell line HS-5.
  • The microenvironment in these cocultures lead to B-CLL cell survival for at least several months and therefore provided a tool for valid in vitro analysis, mimicking the in vivo situation.
  • Although primary B lymphocytes are notoriously resistant to most gene transfer techniques, we achieved high transfection efficiency and cell viability in this coculture system by using a nucleofection-based strategy.
  • Surprisingly, the introduction of circular plasmid DNA into B cells and B-CLL cells induced rapid apoptosis, which was independent of the type of transgene used, but dependent on the DNA concentration.
  • However, transfection of these cells with mRNA was highly efficient and resulted in sustained cell viability and potent transgene expression.
  • The described procedure represents a new approach to study gene function in primary B cells and B-CLL cells.
  • [MeSH-major] Apoptosis / physiology. B-Lymphocytes / cytology. Cell Culture Techniques / methods. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Transfection / methods
  • [MeSH-minor] Cell Survival / physiology. Coculture Techniques. Humans. Nucleic Acids / genetics. Plasmids / pharmacokinetics. RNA, Messenger / pharmacokinetics. RNA, Small Interfering / pharmacokinetics. Stromal Cells / cytology. Transgenes / physiology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637809.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nucleic Acids; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down


75. Ghia EM, Jain S, Widhopf GF 2nd, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ: Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood; 2008 May 15;111(10):5101-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
  • We examined the chronic lymphocytic leukemia (CLL) cells of 2457 patients evaluated by the CLL Research Consortium (CRC) and found that 63 (2.6%) expressed immunoglobulin (Ig) encoded by the Ig heavy-chain-variable-region gene (IGHV), IGHV3-21.
  • Cases that had HCDR3 motif-1 had a median time from diagnosis to initial therapy comparable with that of cases without a defined HCDR3 motif, as did cases that used mutated IGHV3-21 (n = 27) versus unmutated IGHV3-21 (n = 30).
  • This study reveals that CLL cells expressing IGHV3-21/IGLV3-21 most likely were derived from B cells that had experienced somatic mutation and germinal-center maturation in an apparent antigen-driven immune response before undergoing Ig-receptor editing and after germinal-center leukemogenic selection.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2007 Jan;21(1):1-3 [17167526.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):728-40 [16998507.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2989-98 [17148579.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3137-44 [17675554.001]
  • [Cites] Immunity. 1999 Nov;11(5):527-36 [10591178.001]
  • [Cites] Immunity. 1999 Nov;11(5):537-45 [10591179.001]
  • [Cites] J Exp Med. 2000 Oct 16;192(8):1151-64 [11034605.001]
  • [Cites] Immunol Rev. 2000 Aug;176:141-53 [11043774.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5122-6 [11046043.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1001-8 [11159529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1166-70 [11158612.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1892-4 [11263438.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1902-3 [11263445.001]
  • [Cites] Immunity. 2001 Dec;15(6):947-57 [11754816.001]
  • [Cites] J Exp Med. 2002 Jan 21;195(2):181-8 [11805145.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):383-9 [11828014.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2262-4 [11877310.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1097-8; author reply 1098-9 [12130479.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1404-9 [12149224.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2066-70 [12242446.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4609-14 [12393534.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1543-52 [12486097.001]
  • [Cites] Immunity. 2003 Feb;18(2):185-92 [12594946.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4952-7 [12586612.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2725-33 [12928426.001]
  • [Cites] Mol Pathol. 2003 Oct;56(5):249-55 [14514917.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] J Autoimmun. 2004 Mar;22(2):147-52 [14987743.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W435-40 [15215425.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2499-504 [15217828.001]
  • [Cites] Curr Opin Immunol. 2004 Dec;16(6):808-14 [15511677.001]
  • [Cites] J Immunol. 1991 Aug 1;147(3):1060-6 [1907304.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 29;764:463-73 [7486567.001]
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1435-45 [9126924.001]
  • [Cites] J Mol Biol. 1997 Jul 25;270(4):587-97 [9245589.001]
  • [Cites] Curr Opin Immunol. 1998 Apr;10(2):208-13 [9602310.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):688-94 [9710436.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D593-7 [15608269.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1678-85 [15466924.001]
  • [Cites] Haematologica. 2005 Mar;90(3):391-9 [15749671.001]
  • [Cites] Blood. 2005 Jul 15;106(2):681-9 [15817677.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2889-94 [16317103.001]
  • [Cites] Mol Med. 2005 Jan-Dec;11(1-12):52-8 [16622520.001]
  • [Cites] Eur J Immunol. 2006 Jul;36(7):1963-74 [16783849.001]
  • [Cites] Blood. 2007 Jan 1;109(1):259-70 [16985177.001]
  • (PMID = 18326815.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / R37 CA049870; United States / NCI NIH HHS / CA / P01-CA81534; United States / NCI NIH HHS / CA / R37-CA49870
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  • [Other-IDs] NLM/ PMC2384137
  •  go-up   go-down


76. Wiestner A: Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemia. Cytometry B Clin Cytom; 2006 Jul 15;70(4):201-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemia.
  • ZAP-70 has become one of the most studied prognostic markers in Chronic Lymphocytic Leukemia (CLL).
  • ZAP-70 is remarkable in many ways: ZAP-70 has been identified as the best discriminating gene between prognostically distinct CLL subtypes using large scale gene expression profiling; ZAP-70 has been shown to enhance signal transduction in CLL B-cells and therefore could contribute to disease progression; and ZAP-70 is one of the rare examples of an intracellular target considered for clinical flow cytometry.
  • Despite the best effort, one will likely have to accept that not all cases can be clearly assigned to one or the other group, given that ZAP-70 expression between CLL patients falls along a continuum from absent to high.
  • [MeSH-major] Biomarkers, Tumor / analysis. Flow Cytometry / methods. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. ZAP-70 Protein-Tyrosine Kinase / analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 International Society for Analytical Cytology.
  • (PMID = 16906579.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  • [Number-of-references] 19
  •  go-up   go-down


77. Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, del Cerro MH, Van den Steen PE, Opdenakker G, Terol MJ, García-Pardo A: Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood; 2008 Jul 1;112(1):169-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells.
  • As B-cell chronic lymphocytic leukemia (B-CLL) progresses, malignant cells extravasate and infiltrate lymphoid tissues.
  • Although mainly a secreted protease, some MMP-9 is present at the B-CLL cell surface and the function, mode of anchoring, and interactions of this MMP-9 are unknown.
  • Here we show that anti-MMP-9 antibodies immunoprecipitated a 190-kDa CD44v isoform and alpha4beta1 integrin from B-CLL cells, but not from normal B cells.
  • Function-blocking antibodies to alpha4beta1 or CD44, or transfection with specific siRNAs, decreased cell-associated proMMP-9 and increased the secreted form.
  • B-CLL cells attached to and bound proMMP-9 and active MMP-9, and this was inhibited by blocking the expression or function of alpha4beta1 or CD44.
  • The MMP-9 hemopexin domain was critical in these interactions. alpha4beta1 and 190-kDa CD44v (but not CD44H) formed a complex at the cell surface, since they both coimmunoprecipitated with anti-alpha4, anti-beta1, or anti-CD44 antibodies.
  • Binding of proMMP-9 inhibited B-CLL cell migration, and this required MMP-9 proteolytic activity.
  • Thus, we have identified alpha4beta1 and CD44v as a novel proMMP-9 cell surface docking complex and show that cell-associated MMP-9 may regulate B-CLL cell migration and arrest.
  • [MeSH-major] Antigens, CD44 / metabolism. Integrin alpha4beta1 / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Matrix Metalloproteinase 9 / metabolism. Protein Isoforms / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Cell Adhesion. Cell Membrane / immunology. Cell Membrane / metabolism. Cell Movement. Enzyme Precursors / chemistry. Enzyme Precursors / metabolism. Female. Gene Silencing. Genetic Variation. Humans. Male. Middle Aged. Molecular Weight. Multiprotein Complexes. Neoplasm Invasiveness. RNA, Small Interfering / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2008 Jul 1;112(1):5-6 [18574035.001]
  • (PMID = 18326820.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / Enzyme Precursors; 0 / Integrin alpha4beta1; 0 / Multiprotein Complexes; 0 / Protein Isoforms; 0 / RNA, Small Interfering; EC 3.4.24.- / pro-matrix metalloproteinase 9; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


78. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK: Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer; 2009 Nov 18;8:106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression.
  • Cancer precursor/progenitor cells may initiate and sustain the growth of tumors, but evidence for their existence in human disease is indirect, relying on their in vitro properties and animal models.
  • More directly, specific elimination of these rare cells from cancer patients should produce a delayed but progressive disappearance of differentiated malignant progeny.
  • Here, we describe selective eradication of a putative precursor population in a patient with B-cell chronic lymphocytic leukemia, followed 6 months later by a progressive loss of mature tumor cells without further treatment.
  • This outcome supports the presence of a rare population of precursor/progenitor cells in human malignancies, and suggests benefit from their removal.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Nov 1;96(9):2917-24 [11049967.001]
  • [Cites] Leukemia. 2009 Mar;23(3):519-27 [19092852.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Stem Cells. 2002;20(1):11-20 [11796918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1797-806 [8666936.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2406-14 [9516140.001]
  • [Cites] Nature. 1999 Aug 26;400(6747):881-5 [10476968.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6916-23 [16203783.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23 [17202265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):190-7 [18172311.001]
  • [Cites] Cancer Biol Ther. 2007 Sep;6(9):1490-5 [17881904.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):345-9 [18202660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52 [18287027.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12469-73 [18711140.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Nat Biotechnol. 2009 Jan;27(1):44-6 [19131997.001]
  • [Cites] Blood. 2001 May 1;97(9):2777-83 [11313271.001]
  • (PMID = 19922650.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA126752; United States / NCI NIH HHS / CA / P50CA126752
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD5
  • [Other-IDs] NLM/ PMC2784756
  •  go-up   go-down


79. Luo QZ, Li LX, Xie YB, Yan MY, Yu P: [Association of HLA-A, B and DRB1 alleles with leukemia in Han population in Hunan Province]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun;28(6):1016-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of HLA-A, B and DRB1 alleles with leukemia in Han population in Hunan Province].
  • OBJECTIVE: To investigate the association of HLA-A, B, and DRB1 alleles with leukemia in the Han population in Hunan Province.
  • METHODS: HLA-A, B, and DRB1 alleles were genotyped in 105 patients with chronic myelocytic leukemia, 25 with acute lymphocytic leukaemia, and 48 with acute nonlymphocytic leukemia using polymerase chain reaction with sequence-specific primer (PCR-SSP).
  • RESULTS: The phenotypic frequencies of HLA-B58, DR12, and DR14 were significantly higher in patients with chronic myelocytic leukemia than in the control group, with relative risk of 6.1287, 1.6519, and 1.6479, respectively.
  • In patients with acute lymphocytic leukaemia, the phenotypic frequency of HLA-B58 was significantly higher than that in the control group, with the relative risk of 7.4055.
  • In patients with acute nonlymphocytic leukemia, the frequencies of HLA-B58 and DR8 phenotypes were significantly higher but HLA-A24 frequency was significantly lower than those of the control group, with the relative risk of 13.9789, 2.2839, and 0.4012, respectively.
  • CONCLUSION: HLA-B58, DR12, DR14 alleles appear to contribute to the genetic susceptibility of patients with chronic myelocytic leukemia.
  • HLA-B58 allele can be associated with the genetic susceptibility for patients with acute lymphocytic leukaemia.
  • In patients with acute nonlymphocytic leukemia, HLA-B58 and DR8 are probably the susceptible alleles whereas HLA-A24 allele may play a protective role.
  • [MeSH-major] HLA-A Antigens / genetics. HLA-B Antigens / genetics. Leukemia / genetics. Nerve Tissue Proteins / genetics. RNA-Binding Proteins / genetics
  • [MeSH-minor] Alleles. Asian Continental Ancestry Group / genetics. China. Female. Gene Frequency. Genotype. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / ethnology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / ethnology. Leukemia, Myeloid, Acute / genetics. Male. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18583252.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-B Antigens; 0 / Nerve Tissue Proteins; 0 / RBM45 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


80. Mikosik A, Zaremba A, Puchalska Z, Daca A, Smolenska Z, Lopatniuk P, Mital A, Hellman A, Bryl E, Witkowski JM: Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation. Folia Histochem Cytobiol; 2007;45(4):343-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo measurement of calpain activation in human peripheral blood lymphocytes by detection of immunoreactive products of calpastatin degradation.
  • Limited proteolysis of multiple intracellular proteins by endogenous Ca-dependent cysteine proteases--calpains--is an important regulatory mechanism for cell proliferation, apoptosis etc.
  • The calpain-calpastatin system within living cells is in a fragile balance, which depends on both partners.
  • In this work we made an attempt to estimate and compare the activity of calpain in human peripheral blood lymphocytes by assessing the levels of limited proteolysis of calpastatin in these cells by western blot, while at the same time the levels of calpain protein inside these cells was measured by flow cytometry.
  • Our results indicate that it is possible to compare (semi-quantitatively) the activities of calpain in peripheral blood CD4+ and CD19+ lymphocytes from various donors that way.
  • Preliminary results showed that calpain activity is increased in the CD4+ T cells isolated from peripheral blood of rheumatoid arthritis patients as compared to control lymphocytes.
  • Extremely high intrinsic activity of calpain was detected in chronic lymphocytic leukemia (CD19+) cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165173.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD4; 0 / Calcium-Binding Proteins; 0 / Peptide Fragments; 79079-11-1 / calpastatin; EC 3.4.22.- / Calpain
  •  go-up   go-down


81. Reuters I, Weber M, Schulze-Lohoff E: Rho/Rho kinase pathway regulates maintenance of the differentiated tubular epithelial cell phenotype on laminin-1. Nephron Physiol; 2006;104(2):p95-p106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rho/Rho kinase pathway regulates maintenance of the differentiated tubular epithelial cell phenotype on laminin-1.
  • BACKGROUND: Maintenance of a polarized tubular epithelium by appropriate intracellular signaling and extracellular matrix is critical both in normal renal function as well as in acute and chronic tubular injury.
  • We examined the hypothesis that maintenance of a differentiated epithelial phenotype on the basement membrane glycoprotein laminin-1 is controlled by the Rho/Rho kinase pathway.
  • METHODS: Using the tubular epithelial cell lines LLC-PK1 and MDCK which were cultured on laminin-1 vs. collagen IV, we analyzed cell morphology and motility (cohort migration assay) as well as expression of differentiation and dedifferentiation markers (immunofluorescence microscopy).
  • RESULTS: Cohort migration of LLC-PK1 cells was significantly slowed down on laminin-1 (10.7 +/- 2.2 m.u. (migratory units)) compared with collagen IV (16.6 +/- 2.3 m.u.
  • In parallel to the increased migratory activity, inhibition of the Rho/Rho kinase pathway resulted in a more mesenchymal phenotype of LLC-PK1 cells on laminin-1 with increased formation of lamellopodia and filopodia, distinct loss of focal contacts and stress fibers, upregulation of the dedifferentiation marker vimentin, and loss of cell-cell contacts with translocation of beta-catenin from the adherens junctions to the cytosol and nucleus.
  • Similarly, cohort migration of MDCK cells was retarded on laminin-1 when compared with collagen IV, and addition of the Rho kinase inhibitor Y27632 resulted in enhanced motility and a change in cell morphology.
  • CONCLUSION: The study demonstrates that the Rho/Rho kinase pathway is required to maintain a non-migratory epithelial phenotype of cultured renal tubular LLC-PK1 and MDCK cells on the basement membrane glycoprotein laminin-1.
  • [MeSH-minor] Animals. Cell Differentiation. Cell Line. Cell Movement. Dogs. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Phenotype. Signal Transduction / drug effects. Signal Transduction / physiology. Swine. rho-Associated Kinases

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16847378.001).
  • [ISSN] 1660-2137
  • [Journal-full-title] Nephron. Physiology
  • [ISO-abbreviation] Nephron Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Laminin; 0 / laminin 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / rho-Associated Kinases; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


82. Sellick GS, Coleman RJ, Talaban RV, Fleischmann C, Rudd MF, Allinson R, Catovsky D, Houlston RS: Germline mutations in Dok1 do not predispose to chronic lymphocytic leukemia. Leuk Res; 2005 Jan;29(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline mutations in Dok1 do not predispose to chronic lymphocytic leukemia.
  • The genetic basis of familial CLL is poorly understood and to date no gene which when mutated in the germline has been unambiguously shown to confer susceptibility to the disease.
  • Dok1 maps to chromosome 2p13, a region commonly rearranged in CLL.
  • Dok1 inhibits MAP kinase activity, down-regulates cell proliferation and has a suppressive effect on cellular transformation and B-cell signalling pathways.
  • A recent report has implicated mutation of Dok1 in the aetiology of CLL.
  • To examine the proposition that germline mutations in Dok1 act as high penetrance susceptibility alleles for CLL we screened 140 familial cases for functional sequence variants.
  • This result indicates that germline mutations in Dok1 are unlikely to cause an inherited predisposition to CLL.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Phosphoproteins / genetics. RNA-Binding Proteins / genetics
  • [MeSH-minor] Adult. Female. Genetic Predisposition to Disease / genetics. Germ-Line Mutation. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15541476.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / DOK1 protein, human; 0 / Phosphoproteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


83. Virgin F, Zhang S, Schuster D, Azbell C, Fortenberry J, Sorscher EJ, Woodworth BA: The bioflavonoid compound, sinupret, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope; 2010 May;120(5):1051-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Dehydration of airway surface liquid (ASL) disrupts normal mucociliary clearance in sinonasal epithelium leading to chronic rhinosinusitis.
  • Abnormal chloride (Cl(-)) transport is one mechanism that contributes to this disorder, as demonstrated by the disease cystic fibrosis.
  • Sinupret (Bionorica, LLC, San Clemente, CA), a combination of naturally occurring bioflavonoids, is a widely used treatment for respiratory ailments in Europe.
  • METHODS: Well characterized murine nasal septal epithelial (MNSE) cultures, and murine nasal potential difference (NPD) techniques were used to evaluate the effects of Sinupret on Cl(-) secretion.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422703.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chloride Channels; 0 / Chlorides; 0 / Flavonoids; 0 / Plant Extracts; 1F7A44V6OU / Colforsin; 77321-52-9 / Sinupret
  •  go-up   go-down


84. Biebinger R, Zimmermann MB, Al-Hooti SN, Al-Hamed N, Al-Salem E, Zafar T, Kabir Y, Al-Obaid I, Petry N, Hurrell RF: Efficacy of wheat-based biscuits fortified with microcapsules containing ferrous sulfate and potassium iodate or a new hydrogen-reduced elemental iron: a randomised, double-blind, controlled trial in Kuwaiti women. Br J Nutr; 2009 Nov;102(9):1362-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first objective of the study was to measure the efficacy in wheat flour of two newly developed Fe compounds, an H-reduced Fe powder (NutraFine RS; North America Höganäs High Alloys LLC, Johnstown, PA, USA) and small particle-sized (40 microm) encapsulated FeSO4.
  • A randomised, double-blind controlled intervention trial was conducted in Kuwaiti women (n 279; aged 18-35 years) with low body Fe stores (serum ferritin (SF) < 25 microg/l) randomly assigned to one of three groups (20 mg Fe as NutraFine RS, 10 mg Fe as encapsulated FeSO4 and 150 microg iodine, or no fortification Fe) who consumed wheat-based biscuits 5 d per week.
  • Relative to control, mean SF in the encapsulated FeSO4 group increased by 88 % (P < 0.001) and body Fe stores increased from - 0.96 to 2.24 mg/kg body weight (P < 0.001), while NutraFine RS did not significantly increase SF or body Fe stores.
  • The median urinary iodine concentration increased from 140 to 213 microg/l (P < 0.01).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. FERROUS SULFATE .
  • Hazardous Substances Data Bank. POTASSIUM IODATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653920.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Capsules; 0 / Ferrous Compounds; 0 / Hemoglobins; 0 / Iodates; 0 / Iron, Dietary; 0 / Potassium Compounds; 0 / Transferrin; 39R4TAN1VT / ferrous sulfate; E1UOL152H7 / Iron; I139E44NHL / potassium iodate
  •  go-up   go-down


85. Chen Z, Wang Y, Ratia K, Mesecar AD, Wilkinson KD, Baker SC: Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63. J Virol; 2007 Jun;81(11):6007-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human coronavirus NL63 (HCoV-NL63), a common human respiratory pathogen, is associated with both upper and lower respiratory tract disease in children and adults.
  • We generated polyclonal antisera directed against two of the predicted replicase nonstructural proteins (nsp3 and nsp4) and detected replicase proteins from HCoV-NL63-infected LLC-MK2 cells by immunofluorescence, immunoprecipitation, and Western blot assays.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2004 Jun;78(11):5957-65 [15140993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7 [15226499.001]
  • [Cites] Nucleic Acids Res. 2004;32(14):e115 [15304544.001]
  • [Cites] J Virol. 2004 Sep;78(18):9977-86 [15331731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1967 Apr;57(4):933-40 [5231356.001]
  • [Cites] J Virol. 1999 Apr;73(4):2658-66 [10074111.001]
  • [Cites] J Virol. 1999 Jul;73(7):5957-69 [10364348.001]
  • [Cites] J Virol. 2004 Dec;78(24):13600-12 [15564471.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1374-8 [15531891.001]
  • [Cites] Curr Top Microbiol Immunol. 2005;287:57-94 [15609509.001]
  • [Cites] J Virol. 2005 Jan;79(2):884-95 [15613317.001]
  • [Cites] J Infect Dis. 2005 Feb 15;191(4):503-6 [15655772.001]
  • [Cites] J Med Virol. 2005 Mar;75(3):463-5 [15648061.001]
  • [Cites] J Med Virol. 2005 Mar;75(3):455-62 [15648064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5 [15695582.001]
  • [Cites] J Virol. 2005 Apr;79(7):4550-1 [15767458.001]
  • [Cites] Clin Infect Dis. 2005 Jun 15;40(12):1721-9 [15909257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93 [15897467.001]
  • [Cites] Pediatr Infect Dis J. 2005 Jul;24(7):645-6 [15999010.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):599-609 [16064136.001]
  • [Cites] Emerg Infect Dis. 2005 Aug;11(8):1225-9 [16102311.001]
  • [Cites] Mol Cell. 2005 Aug 19;19(4):547-57 [16109378.001]
  • [Cites] PLoS Med. 2005 Aug;2(8):e240 [16104827.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4567-73 [16145108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5 [16169905.001]
  • [Cites] PLoS Biol. 2005 Oct;3(10):e324 [16128623.001]
  • [Cites] Essays Biochem. 2005;41:139-56 [16250903.001]
  • [Cites] J Med Chem. 2005 Nov 3;48(22):6767-71 [16250632.001]
  • [Cites] Science. 2005 Oct 28;310(5748):676-9 [16195424.001]
  • [Cites] Structure. 2005 Nov;13(11):1665-75 [16271890.001]
  • [Cites] J Gen Virol. 1967 Apr;1(2):175-8 [4293939.001]
  • [Cites] Virology. 1992 Jul;189(1):274-84 [1318604.001]
  • [Cites] Virology. 1995 Jun 1;209(2):420-7 [7778277.001]
  • [Cites] Virology. 1995 Jun 1;209(2):489-97 [7539970.001]
  • [Cites] J Virol. 1997 Feb;71(2):900-9 [8995606.001]
  • [Cites] J Virol. 2000 Feb;74(4):1674-85 [10644337.001]
  • [Cites] J Virol. 2000 Sep;74(17):7911-21 [10933699.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33220-32 [11431476.001]
  • [Cites] Virology. 1995 Apr 1;208(1):1-8 [11831690.001]
  • [Cites] J Virol. 2002 Apr;76(8):3697-708 [11907209.001]
  • [Cites] J Virol. 2002 Jun;76(12):6323-31 [12021365.001]
  • [Cites] Chem Biol. 2002 Oct;9(10):1149-59 [12401499.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1319-25 [12711465.001]
  • [Cites] N Engl J Med. 2003 May 15;348(20):1967-76 [12690091.001]
  • [Cites] N Engl J Med. 2003 May 15;348(20):1953-66 [12690092.001]
  • [Cites] J Virol. 2003 Jul;77(13):7376-82 [12805436.001]
  • [Cites] J Gen Virol. 2003 Sep;84(Pt 9):2305-15 [12917450.001]
  • [Cites] J Virol. 2003 Oct;77(19):10515-27 [12970436.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:141-72 [14570567.001]
  • [Cites] J Biol Chem. 2004 Mar 12;279(11):10136-41 [14699140.001]
  • [Cites] Emerg Infect Dis. 2004 Feb;10(2):320-6 [15030705.001]
  • [Cites] Nat Med. 2004 Apr;10(4):368-73 [15034574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6212-6 [15073334.001]
  • [Cites] Pediatr Infect Dis J. 2005 Nov;24(11):1015-7 [16282944.001]
  • [Cites] J Virol. 2005 Dec;79(24):15189-98 [16306590.001]
  • [Cites] J Virol. 2005 Dec;79(24):15199-208 [16306591.001]
  • [Cites] J Virol. 2005 Dec;79(24):15582-5 [16306630.001]
  • [Cites] Virol J. 2004;1:7 [15548333.001]
  • [Cites] Cell. 2005 Dec 2;123(5):773-86 [16325574.001]
  • [Cites] Proteins. 2006 Mar 15;62(3):760-75 [16358325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22 [16581910.001]
  • [Cites] J Virol. 2006 May;80(9):4211-9 [16611880.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8 [16723558.001]
  • [Cites] J Virol. 2006 Jun;80(12):5927-40 [16731931.001]
  • [Cites] J Virol. 2006 Jun;80(12):6003-12 [16731939.001]
  • [Cites] PLoS Pathog. 2005 Dec;1(4):e39 [16341254.001]
  • [Cites] Clin Infect Dis. 2006 Sep 1;43(5):585-92 [16886150.001]
  • [Cites] J Virol. 2006 Sep;80(17):8639-52 [16912312.001]
  • [Cites] J Virol. 2006 Dec;80(23):11610-20 [16971428.001]
  • (PMID = 17392370.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P01 AI060915; United States / NIAID NIH HHS / AI / P01-AI060915; United States / PHS HHS / / R01-A1045798
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ubiquitin; 0 / Viral Envelope Proteins; EC 3.4.22.- / 3C-like proteinase, Coronavirus; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.2 / Papain
  • [Other-IDs] NLM/ PMC1900296
  •  go-up   go-down


86. Abrams ST, Brown BR, Zuzel M, Slupsky JR: Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells. Blood; 2010 Jun 3;115(22):4447-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells.
  • Chronic lymphocytic leukemia (CLL) is a malignant disease of mature B lymphocytes.
  • We have previously shown that a characteristic feature of CLL cells are high levels of expression and activity of protein kinase CbetaII (PKCbetaII), and that this might influence disease progression by modulating signaling in response to B-cell receptor engagement.
  • The aim of the present work was to investigate the factors involved in stimulating PKCbetaII expression in CLL cells.
  • Here we show that the activation of PKCbetaII in CLL cells stimulated with vascular endothelial growth factor (VEGF) can drive expression of the gene for PKCbeta, PRKCB1.
  • We found that this effect of VEGF on PRKCB1 transcription is paralleled by high expression of PKCbetaII protein and therefore probably contributes to the malignant phenotype of CLL cells.
  • Taken together, the data presented in this study demonstrate that VEGF, in addition to its role in providing prosurvival signals, also plays a role in overexpression of PKCbetaII, an enzyme with a specific pathophysiologic role in CLL.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Protein Kinase C / genetics. Protein Kinase C / metabolism. Vascular Endothelial Growth Factor A / pharmacology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Jun 3;115(22):4325-6 [20522718.001]
  • (PMID = 20164467.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate; 0 / DNA Primers; 0 / Mesylates; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Recombinant Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Agammaglobulinaemia tyrosine kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.13 / PRKCB protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  •  go-up   go-down


87. Pamuk GE, Uyanik MS, Demir M, Tekgündüz E, Turgut B, Soy M: Systemic antineutrophil cytoplasmic antibody vasculitis in a patient with chronic lymphocytic leukemia: quite a rare diagnosis. Leuk Res; 2007 Aug;31(8):1149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic antineutrophil cytoplasmic antibody vasculitis in a patient with chronic lymphocytic leukemia: quite a rare diagnosis.
  • There might be rheumatic manifestations of malignant diseases, especially those of the hematological type.
  • Until now, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in chronic lymphocytic leukemia (CLL) has been reported on only very few occasions.
  • Here, we present our patient with Rai stage II CLL who came to us with constitutional symptoms.
  • Constitutional symptoms in patients with hematological malignancies should make the physicians consider systemic vasculitis after exclusion of disease-related complications.
  • [MeSH-major] Antibodies, Antineutrophil Cytoplasmic / blood. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Vasculitis, Leukocytoclastic, Cutaneous / blood


88. Scamardella F, Maconi M, Albertazzi L, Gamberi B, Gugliotta L, Brini M: Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients. Lab Hematol; 2006;12(4):187-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
  • B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disease caused by impaired apoptosis regulation that leads to an abnormal survival and an accumulation of B-lymphocytes.
  • Anti-apoptotic Bcl-2 and proapoptotic Bax proteins are involved in the highly regulated mechanism of cell death.
  • Bax and Bcl-2 intracellular levels were analyzed both in CD19+ and CD3+ cells from 28 B-CLL de novo patients and compared with cells from healthy donors.
  • In CD19+ B-CLL cells, the Bax/Bcl-2 ratio was lower than in the CD19+ normal counterpart (1.3 versus 3.51; P<.05), mainly due to a Bcl-2 over expression (17.65 versus 9.02; P<.001).
  • In CD3+ cells from B-CLL patients, the Bax/Bcl-2 ratio was lower than in normal CD3+ cells (7.89 versus 8.96; P<.005), most importantly as a result of Bax suppression (77.22 versus 96.63; P<.001).
  • These study data show an apoptosis inhibition not only in CD19+ cells, but also in CD3+ cells, suggesting a pivotal role of T-cells in B-CLL pathogenesis.
  • [MeSH-major] Apoptosis / physiology. B-Lymphocytes / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. T-Lymphocytes / metabolism. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118768.001).
  • [ISSN] 1080-2924
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD3; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


89. Carlo-Stella C, Di Nicola M, Turco MC, Cleris L, Lavazza C, Longoni P, Milanesi M, Magni M, Ammirante M, Leone A, Nagy Z, Gioffrè WR, Formelli F, Gianni AM: The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res; 2006 Feb 1;66(3):1799-808
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
  • The fully human anti-HLA-DR antibody 1D09C3 has been shown to delay lymphoma cell growth in severe combined immunodeficient (SCID) mice.
  • The present study was aimed at (a) investigating the mechanism(s) of 1D09C3-induced cell death and (b) further exploring the therapeutic efficacy of 1D09C3 in nonobese diabetic (NOD)/SCID mice.
  • The chronic lymphocytic leukemia cell line JVM-2 and the mantle cell lymphoma cell line GRANTA-519 were used.
  • Generation of reactive oxygen species (ROS) and mitochondrial membrane depolarization were measured by flow cytometry following cell incubation with dihydroethidium and TMRE, respectively.
  • In vitro, 1D09C3-induced cell death involves a cascade of events, including ROS increase, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria.
  • In vivo, 1D09C3 induces long-term disease-free survival in a significant proportion of tumor-bearing mice treated at an early stage of disease.
  • Treatment of mice bearing advanced-stage lymphoma results in a highly significant prolongation of survival.
  • These data show that 1D09C3 (a) exerts a potent antitumor effect by activating ROS-dependent, JNK-driven cell death, (b) cures the great majority of mice treated at an early-stage of disease, and (c) significantly prolongs survival of mice with advanced-stage disease.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. HLA-DR Antigens / immunology. Lymphoma, Non-Hodgkin / therapy. Mitochondria / drug effects
  • [MeSH-minor] Animals. Cell Death / drug effects. Cell Death / immunology. Cell Growth Processes / drug effects. Cell Growth Processes / immunology. Cell Line, Tumor. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Mice. Mice, Inbred NOD. Mice, SCID. Reactive Oxygen Species / metabolism. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452241.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / HLA-DR Antigens; 0 / Reactive Oxygen Species
  •  go-up   go-down


90. Storey R, Gatt M, Bradford I: Mucosa associated lymphoid tissue lymphoma presenting within a solitary anti-mesenteric dilated segment of ileum: a case report. J Med Case Rep; 2009;3:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa associated lymphoid tissue lymphoma presenting within a solitary anti-mesenteric dilated segment of ileum: a case report.
  • INTRODUCTION: Mucosa associated lymphoid tissue (MALT) lymphoma is the third most common non-Hodgkin's lymphoma subtype.
  • Clinical presentation is often insidious as a low-grade lesion and disease tends to remain localised for a long period of time.
  • Histology of this segment demonstrated MALT lymphoma of the small bowel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2008;43(4):497-505 [18365916.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):529-33 [15729078.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):527-37 [9389360.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2486-92 [10561313.001]
  • [Cites] Arch Surg. 1994 Jun;129(6):659-61 [8204043.001]
  • [Cites] Cancer. 1983 Jan 1;51(1):80-91 [6336974.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • (PMID = 19126231.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2627909
  •  go-up   go-down


91. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I: Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol; 2005 Sep 20;23(27):6719-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
  • PATIENTS AND METHODS: Forty-six pretreated patients with CD22+ non-Hodgkin's lymphoma (NHL; n = 4), chronic lymphocytic leukemia (CLL; n = 11), and hairy cell leukemia (HCL; n = 31) received 265 cycles at 3 to 50 microg/Kg every other day x 3 doses.
  • The CR rate was 86% in patients enrolled at > or = 40 microg/Kg every other day x 3, and 41% at lower doses (P = .011).
  • The median duration for CR was 36 months (range, 5 to 66 months), and eight patients remain in CR at 45 months (range, 29 to 66 months).
  • Lower but significant activity occurred in CLL.
  • CONCLUSION: BL22 was well tolerated and highly effective in HCL, even after one cycle.
  • [MeSH-major] Immunotoxins / therapeutic use. Leukemia, Hairy Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061911.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Enterotoxins; 0 / Immunotoxins; 0 / RFB4(dsFv)-PE38 recombinant immunotoxin
  •  go-up   go-down


92. Lin K, Rockliffe N, Johnson GG, Sherrington PD, Pettitt AR: Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene; 2008 Apr 10;27(17):2445-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
  • In chronic lymphocytic leukaemia (CLL), mutation/deletion of TP53 is strongly associated with early disease progression, resistance to chemotherapy and short patient survival.
  • Primary CLL cells of defined ataxia telangiectasia mutated (ATM)/p53 status were incubated with the Hsp90 inhibitor geldanamycin (GA) and analysed by western blotting for the expression of p53, p21, MDM2 and Akt.
  • GA downregulated overexpressed mutant p53 protein (an oncogene) and upregulated wild-type (wt) p53 (a tumour suppressor).
  • GA also produced a p53/ATM-independent increase in the levels of p21-a potent inducer of cell-cycle arrest.
  • In-vitro cytotoxicity studies showed that GA killed cultured CLL cells in a dose- and time-dependent fashion irrespective of their p53/ATM status and more effectively than normal blood mononuclear cells.
  • In summary, our findings reveal important consequences of inhibiting Hsp90 in CLL cells and strongly support the therapeutic evaluation of Hsp90 inhibitors in poor-prognosis patients with p53 defects.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. DNA-Binding Proteins / metabolism. Gene Expression Regulation / drug effects. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Mutant Proteins / metabolism. Protein-Serine-Threonine Kinases / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Benzoquinones / toxicity. Cell Survival / drug effects. Humans. Kinetics. Lactams, Macrocyclic / toxicity. Mutation / genetics. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-mdm2 / metabolism. Signal Transduction / drug effects. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982489.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / Mutant Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2; Z3K3VJ16KU / geldanamycin
  •  go-up   go-down


93. Steininger C, Rassenti LZ, Vanura K, Eigenberger K, Jäger U, Kipps TJ, Mannhalter C, Stilgenbauer S, Popow-Kraupp T: Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest; 2009 Jun;39(6):497-506
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia.
  • BACKGROUND: Herpes virus infections may have a significant role in chronic lymphocytic leukaemia (CLL) due to their ability to modulate the host's immune system.
  • MATERIALS AND METHODS: We examined the seroprevalence of four herpes viruses [Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), human herpes virus (HHV)-6 and -7] in a cohort of European CLL patients (cohort 1, n = 100) in relation to the immunoglobulin variable heavy (IGHV) chain gene use and compared serological results with those obtained from age- and gender-matched healthy adults (n = 100).
  • RESULTS: CMV-seroprevalence was significantly higher in CLL cohort 1 (79%) than in the control cohort (57%, P = 0.001); the seroprevalence of EBV (89% vs. 94%), HHV-6 (73% vs. 60%), or HHV-7 (35% vs. 35%) was not.
  • In CLL cohort 1, use of IGHV3-30 was more prevalent among CMV-seropositive and of IGHV3-21 among HHV-7-seronegative cases.
  • To investigate the generalizability of these findings, we investigated the herpes virus seroprevalence in a second cohort of age-matched CLL patients from a different geographical area (USA, n = 100, cohort 2).
  • In CLL cohort 2, use of IGHV3-30 or IGHV3-21 was not associated with any of the herpes viruses investigated.
  • CONCLUSIONS: CMV-seropositivity is associated with CLL in selected patient cohorts.
  • However, the considerable variation in herpes virus-specific seropositivity between geographically distinct CLL cohorts indicates that seropositivity for any of the four human herpes viruses investigated is not generally associated with CLL.
  • [MeSH-major] Cytomegalovirus Infections / immunology. Epstein-Barr Virus Infections / immunology. Herpesviridae Infections / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2337-42 [16618945.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Leukemia. 2009 May;23(5):919-24 [19148139.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] J Med Virol. 2002 Aug;67(4):522-7 [12115998.001]
  • [Cites] J Infect Dis. 2003 May 15;187(10):1571-80 [12721937.001]
  • [Cites] Asian Pac J Allergy Immunol. 2003 Mar;21(1):49-53 [12931751.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2092-9 [14764674.001]
  • [Cites] Ann Intern Med. 1984 Feb;100(2):213-8 [6318632.001]
  • [Cites] Am J Med. 1987 Mar 23;82(3 Spec No):593-601 [3030101.001]
  • [Cites] Transfusion. 1988 Mar-Apr;28(2):187-9 [2895517.001]
  • [Cites] J Clin Microbiol. 1989 Apr;27(4):651-3 [2542358.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):829-33 [2159435.001]
  • [Cites] J Med Virol. 1991 Jul;34(3):194-8 [1655969.001]
  • [Cites] Haematologica. 1993 Nov-Dec;78(6):374-7 [8175032.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):381-94 [8001009.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Intervirology. 1996;39(5-6):401-12 [9130049.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Apr 10;14(6):533-6 [9566556.001]
  • [Cites] Trends Microbiol. 1998 May;6(5):190-7 [9614343.001]
  • [Cites] Vox Sang. 1998;75(3):193-7 [9852406.001]
  • [Cites] J Infect Dis. 2004 Dec 1;190(11):1908-12 [15529253.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1678-85 [15466924.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1797-805 [15965501.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2018-25 [15914560.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Pathol Int. 2006 Mar;56(3):112-6 [16497243.001]
  • [Cites] Acta Microbiol Immunol Hung. 2006 Mar;53(1):25-34 [16696548.001]
  • [Cites] Cytometry B Clin Cytom. 2006 Jul 15;70(4):209-13 [16906583.001]
  • [Cites] Clin Infect Dis. 2006 Nov 1;43(9):1143-51 [17029132.001]
  • [Cites] Transplantation. 2006 Oct 15;82(7):979-82 [17038915.001]
  • [Cites] Clin Vaccine Immunol. 2006 Nov;13(11):1181-4 [16957061.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2198-201 [17082317.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3137-44 [17675554.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4609-16 [18768393.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1912-6 [18838479.001]
  • [Cites] J Infect Dis. 2000 Dec;182(6):1761-4 [11069250.001]
  • (PMID = 19490058.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / J 2750; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / 5 PO1-CA081534
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ EMS53772; NLM/ PMC3709071
  •  go-up   go-down


94. Pérez-Chacón G, Contreras-Martín B, Cuní S, Rosado S, Martín-Donaire T, Losada-Fernández I, Vargas JA, Jordá J, Alvarez N, García-Marco J, Pérez-Aciego P: Polymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Am J Clin Pathol; 2005 May;123(5):646-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
  • Despite the low incidence of microsatellite instability (MSI) in lymphoid malignant neoplasms, it has been reported that the CD5 promoter MSI was relatively frequent among B-cell chronic lymphoproliferative disorders.
  • We studied the presence of MSI in the CD5 promoter in 134 cases of B-cell chronic lymphocytic leukemia (B-CLL) and 47 of mantle cell lymphoma (MCL) by comparing the pattern of microsatellite repeats on autologous germline and tumor DNA samples.
  • However, the allele distribution of this polymorphism showed a higher frequency of the 18 CA allele (0.585) in MCL cases (P = .026; odds ratio [OR], 1.75; 95% confidence interval [CI], 1.07-2.87) and of the 19 CA allele (0.179) in B-CLL cases (P = .005; OR, 2.26; 95% CI, 1.27-4.01) compared with control cases (0.442 and 0.087, respectively).
  • This suggests that although MSI seems not to be involved in the pathogenesis of these 2 lymphoid malignant neoplasms, the polymorphic CD5 promoter is associated with increased susceptibility to these disorders.
  • [MeSH-major] Antigens, CD5 / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, Mantle-Cell / genetics. Polymorphism, Genetic. Promoter Regions, Genetic
  • [MeSH-minor] DNA, Neoplasm / analysis. Gene Frequency. Genetic Predisposition to Disease. Humans. Microsatellite Repeats / genetics. Odds Ratio


95. Wlodarski MW, Nearman Z, Jiang Y, Lichtin A, Maciejewski JP: Clonal predominance of CD8(+) T cells in patients with unexplained neutropenia. Exp Hematol; 2008 Mar;36(3):293-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: T-cell-mediated autoimmunity may be involved in some cases of idiopathic neutropenia.
  • We hypothesized that a precise T-cell receptor repertoire analysis may uncover cytotoxic T-cell (CTL) expansions that are less pronounced than those seen in T large granular lymphocyte leukemia (T-LGL), but are pathophysiologically analogous and thus can serve as markers of a T-cell-mediated process.
  • MATERIALS AND METHODS: Using rational algorithms for T-cell receptor analysis and in vivo tracking of CTL responses previously established in our laboratory, we studied patients with unexplained chronic neutropenia (n = 20), T-LGL (n = 15), and healthy controls (n = 12).
  • In comparison to LGL leukemia, these clones were less immunodominant, but clearly discernible from subclinical lymphoproliferations in controls.
  • CONCLUSIONS: These results suggest that, while immunodominant CTL clones are detectable in a proportion of patients only, CTL-mediated pathophysiology may be a general mechanism operating in idiopathic neutropenia.
  • Oligogoclonal CTL expansions in chronic neutropenia may indicate an ongoing autoimmune process, while highly polarized monoclonalities in a subset of neutropenic LGL patients may represent the "extreme" end of the clonal continuum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Blood. 1991 Aug 15;78(4):1096-104 [1678288.001]
  • [Cites] Blood. 1994 Jul 15;84(2):625-31 [7517722.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] J Immunol. 1997 May 1;158(9):4493-9 [9127016.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):123-6 [9136951.001]
  • [Cites] Blood. 1998 Jan 1;91(1):181-6 [9414283.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):278-84 [9920952.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1797-802 [10477706.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:63-79 [15561677.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):863-76 [15755293.001]
  • [Cites] Br J Haematol. 2005 May;129(3):411-9 [15842666.001]
  • [Cites] Autoimmun Rev. 2005 Jun;4(5):315-21 [15990080.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2769-80 [15914562.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2632-41 [16614248.001]
  • [Cites] Blood. 2001 Jul 1;98(1):165-73 [11418476.001]
  • [Cites] J Clin Invest. 2001 Sep;108(5):765-73 [11544283.001]
  • [Cites] Eur J Haematol. 2001 Jul;67(1):35-44 [11553265.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1861-8 [11696446.001]
  • [Cites] J Intern Med. 2001 Dec;250(6):476-91 [11902816.001]
  • [Cites] Semin Hematol. 2002 Apr;39(2):75-81 [11957188.001]
  • [Cites] Semin Hematol. 2002 Apr;39(2):113-20 [11957194.001]
  • [Cites] Semin Hematol. 2002 Apr;39(2):121-7 [11957195.001]
  • [Cites] Autoimmun Rev. 2003 Jun;2(4):218-23 [12848949.001]
  • [Cites] Nat Med. 2003 Sep;9(9):1123-4 [12937414.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1960-9 [14734782.001]
  • [Cites] In Silico Biol. 2004;4(1):17-29 [15089751.001]
  • [Cites] Lancet. 2004 Jul 24-30;364(9431):355-64 [15276395.001]
  • [Cites] Exp Hematol. 2004 Oct;32(10):1010-22 [15504556.001]
  • [Cites] N Engl J Med. 1975 Oct 9;293(15):748-53 [1172188.001]
  • [Cites] Clin Exp Immunol. 1980 Feb;39(2):307-14 [7389203.001]
  • [Cites] J Clin Invest. 1985 Jan;75(1):119-23 [3838096.001]
  • [Cites] Br J Haematol. 1986 May;63(1):59-67 [3085703.001]
  • [Cites] Blood. 1986 Nov;68(5):1095-100 [3490286.001]
  • [Cites] J Exp Med. 1986 Dec 1;164(6):2089-94 [3023520.001]
  • [Cites] Medicine (Baltimore). 1987 Sep;66(5):397-405 [3626848.001]
  • [Cites] Blood. 1988 Mar;71(3):822-4 [3345349.001]
  • [Cites] Nature. 1988 Aug 4;334(6181):395-402 [3043226.001]
  • [Cites] J Clin Invest. 1989 May;83(5):1676-81 [2523415.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1688-91 [2478590.001]
  • [Cites] Blood. 1990 Jan 1;75(1):213-7 [2136803.001]
  • [Cites] Blood. 1990 Feb 1;75(3):736-43 [2297575.001]
  • [Cites] Science. 1993 Oct 15;262(5132):422-4 [8211163.001]
  • (PMID = 18279717.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113972-04; United States / NCRR NIH HHS / RR / U54 RR 019391; United States / NCRR NIH HHS / RR / U54 RR019397-05S16959; United States / NCI NIH HHS / CA / CA 113972-01; United States / NHLBI NIH HHS / HL / R01 HL 73429; United States / NCI NIH HHS / CA / R01 CA113972; United States / NCRR NIH HHS / RR / RR019397-05S16959; United States / NHLBI NIH HHS / HL / R01 HL073429-04; United States / NCI NIH HHS / CA / R01 CA113972-04; United States / NHLBI NIH HHS / HL / HL073429-04; United States / NCRR NIH HHS / RR / U54 RR019397; United States / NHLBI NIH HHS / HL / R01 HL073429; United States / NCRR NIH HHS / RR / S10 RR019391
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS83525; NLM/ PMC2643087
  •  go-up   go-down


96. Masago M, Takaai M, Sakata J, Horie A, Ito T, Ishida K, Taguchi M, Hashimoto Y: Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells. Biol Pharm Bull; 2010;33(8):1407-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells.
  • The aim of the present study was to compare the membrane transport mechanisms of procainamide with those of quinidine using renal epithelial LLC-PK(1) and intestinal epithelial LS180 cells.
  • In LLC-PK(1) cells, the transcellular transport of 10 microM quinidine in the basolateral-to-apical direction was similar to that in the opposite direction, and 1 mM tetraethylammonium (TEA) did not affect the transcellular transport of the drug.
  • On the other hand, the transcellular transport of 10 microM TEA and procainamide in LLC-PK(1) cells was directional from the basolateral side to the apical side.
  • [MeSH-major] Anti-Arrhythmia Agents / pharmacokinetics. Cell Membrane / metabolism. Intestines / metabolism. Kidney / metabolism. Procainamide / pharmacokinetics. Quinidine / pharmacokinetics
  • [MeSH-minor] Animals. Biological Transport, Active. Caco-2 Cells. Cation Transport Proteins / metabolism. Drug Interactions. Epithelial Cells / metabolism. Humans. Hydrogen-Ion Concentration. LLC-PK1 Cells. Swine. Temperature. Tetraethylammonium / pharmacology

  • Hazardous Substances Data Bank. PROCAINAMIDE .
  • Hazardous Substances Data Bank. QUINIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686239.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Cation Transport Proteins; 66-40-0 / Tetraethylammonium; ITX08688JL / Quinidine; L39WTC366D / Procainamide
  •  go-up   go-down


97. Wang J, Zhang B, Guo Y, Li G, Xie Q, Zhu B, Gao J, Chen Z: Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology; 2008;82(2):148-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously reported that dihydroartemisinin is found to have a potent ability in influencing lymphatic endothelial cell migration and tube formation.
  • In this study, we investigated the effect of artemisinin on tumor growth, lymphangiogenesis, metastasis and survival in mouse Lewis lung carcinoma (LLC) models.
  • Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression.
  • [MeSH-minor] Administration, Oral. Animals. Female. Gene Expression Regulation, Neoplastic / drug effects. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Lymphangiogenesis / drug effects. Lymphatic Metastasis / prevention & control. Mice. Mice, Inbred C57BL. Neoplasm Metastasis / prevention & control. Survival Rate. p38 Mitogen-Activated Protein Kinases / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18667841.001).
  • [ISSN] 1423-0313
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Artemisinins; 0 / Vascular Endothelial Growth Factor C; 9RMU91N5K2 / artemisinine; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


98. Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE: A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol; 2010 Feb;148(4):544-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia.
  • Deletion 13q14 on fluorescence in situ hybridization (FISH) analysis is the most common cytogenetic abnormality in chronic lymphocytic leukaemia (CLL), and is a favourable prognostic biomarker when detected as a sole abnormality.
  • We intensively interrogated clinical outcome in 323 consecutive, untreated CLL patients with isolated 13q- identified within 2 years of diagnosis.
  • Patients with a heterozygous 13q- and those with a homozygous deletion had similar time to first treatment (TFT) and overall survival (OS).
  • In contrast, a higher percentage of 13q- nuclei was associated with significantly shorter TFT (P < 0.001).
  • The 5-year untreated rate was 79% for patients with isolated 13q- in < or =65.5% of nuclei compared to 38% among those with 13q- in >65.5% of nuclei (P < 0.001).
  • The percentage of nuclei exhibiting 13q- remained an independent predictor of TFT after controlling for ZAP-70, IGHV, or CD38 (all P < 0.001).
  • Among patients with 13q- plus one other FISH abnormality, concomitant 13q- appeared to attenuate the shorter survival associated with 17p- (P = 0.019).
  • The clinical implications of 13q- in CLL appear more complex than originally appreciated.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Blood. 2009 Jul 30;114(5):957-64 [19414856.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Eur J Haematol. 2008 Aug;81(2):94-9 [18462257.001]
  • [Cites] Haematologica. 2009 Mar;94(3):364-71 [19252174.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4634-41 [17008705.001]
  • (PMID = 19895615.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA095241; None / None / / R01 CA095241-07; United States / NCI NIH HHS / CA / CA95241; United States / NCI NIH HHS / CA / R01 CA095241-07
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS163763; NLM/ PMC2866061
  •  go-up   go-down


99. Sleep 2009. Abstracts of the 23rd Annual Meeting of the Associated Professional Sleep Societies, LLC. June 6-11, 2009. Seattle, Washington, USA. Sleep; 2009;32 Suppl:A1-427
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sleep 2009. Abstracts of the 23rd Annual Meeting of the Associated Professional Sleep Societies, LLC. June 6-11, 2009. Seattle, Washington, USA.

  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760817.001).
  • [ISSN] 0161-8105
  • [Journal-full-title] Sleep
  • [ISO-abbreviation] Sleep
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] United States
  •  go-up   go-down


100. Brenner H, Gondos A, Pulte D: Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood; 2008 May 15;111(10):4916-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century.
  • Although chronic lymphocytic leukemia (CLL) has remained incurable with standard treatments, newer therapeutic approaches, such as chemoimmunotherapy or stem cell transplantation, bear the potential for prolonged survival.
  • We estimated trends in age-specific 5- and 10-year absolute and relative survival of CLL patients in the United States between 1980-1984 and 2000-2004 from the 1973 to 2004 database of the Surveillance, Epidemiology, and End Results Program.
  • Overall, 5- and 10-year absolute survival from diagnosis increased from 54.2% to 60.2% (+6 percentage points; P < .0001) and from 27.8% to 34.8% (+7 percentage points; P < .0001), respectively.
  • In contrast, increases in 10-year absolute and relative survival close to or well above 10% units were observed for all patients younger than 80 years of age at diagnosis compared with no increase at all for older patients.
  • Long-term survival expectations of patients with CLL have substantially improved over the past 2 decades except for patients 80 years of age or older at the time of diagnosis.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Survival Rate / trends

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18309034.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down